Document:

Exhibit 10.10

 Exhibit 10.10 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested 

Under 17 CFR §§ 200.80(b)(4) and 230.406 
 PRODUCTION AGREEMENT 
 THIS PRODUCTION AGREEMENT (the
“Agreement”), effective as of June 26, 2009 (the “Effective Date”), by and between LIPOSCIENCE, INC., a Delaware corporation, (“LipoScience”) and KMC SYSTEMS, INC., a Delaware
corporation (“KMC”). Capitalized terms used in this Agreement and not defined in this Agreement have the meaning given them in the Development Agreement. 
 WHEREAS, LipoScience possesses proprietary technology and information related to the Instrument (as defined in Section 1); 

WHEREAS, KMC has expertise in the design, development and manufacture of medical instrumentation and equipment; and 

WHEREAS, LipoScience desires to appoint KMC, and KMC desires to accept LipoScience’s appointment, as LipoScience’s
exclusive manufacturer of the Instrument on the terms and conditions set forth herein. 
 NOW, THEREFORE, in
consideration of the mutual representations, warranties and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 

 

	 	1.	DEFINITIONS 

 As used in
this Agreement: 
 1.1 “Affiliate” means any corporation, firm, partnership or other entity that controls, is
controlled by, or is under common control, with a party. For the purposes of this definition, “control” shall mean the ownership of at least 50% of the voting share interests of such entity or any other comparable equity or ownership
interest. 
 1.2 “ATP” means the Acceptance Testing Procedures developed by KMC and mutually reviewed and
approved by LipoScience and KMC. 
 1.3 “Business Day” means a day that is not Saturday, Sunday or a federal,
New Hampshire or North Carolina holiday on which commercial banks are closed for business in New Hampshire or North Carolina. 

1.4 “Development Agreement” means that certain Development Agreement dated November 16, 2007 between KMC Systems,
Inc. and LipoScience, Inc. 
 1.5 “Dollars” or “$” means United States dollars. 

1.6 “ECO” means an Engineering Change Order, a standard KMC document used to control incorporation of changes in the
TDP, as set forth in Section 9.2 hereof. 

  
 1 

 1.7 “Forecast” shall have the meaning set forth in Section 7.1 hereof.

 1.8 “Effective Date” shall have the meaning set forth in the introduction to this Agreement. 

1.9 “FDA” means the United States Food and Drug Administration or any successor agency thereof. 

1.10 “Initial Term” shall have the meaning set forth in Section 13.1 hereof. 

1.11 “Instrument” means a commercial production unit of the Numera, based upon the technology and consisting of the
elements described in Appendix I attached to this Agreement and made a part hereof, together with all future upgrades, modifications and derivatives thereof manufactured by KMC pursuant to this Agreement. 

1.12 “Intellectual Property” means all patentable and unpatentable inventions, ideas, discoveries, improvements,
design rights, works of authorship, copyrights, patents, patent applications, trade secrets, know-how and any equivalent thereof; notwithstanding the foregoing, Intellectual Property excludes the [***] and any [***], and any [***] and [***] related
to the [***] and [***] by [***]. 
 1.13 “ISO” means maintaining a quality system certified by a notified body
to the International Standards Organization Quality System Standard ISO 13485. 
 1.14 “Marks” shall have the
meaning set forth in Section 5.4 hereof. 
 1.15 [***] means that certain [***] between [***] and [***] regarding [***]
planned [***] for the [***]. 
 1.16 “Purchase Commitment” shall have the meaning set forth in Section 7.2
hereof. 
 1.17 “Purchase Order” shall have the meaning set forth in Section 6.1 hereof. 

1.18 “QSR” means the Quality System Regulation 21 of the Code of Federal Regulations, part 820, for the development and
manufacture of medical devices and in-vitro diagnostic products. 
 1.19 “Quality Plan” means the KMC
Manufacturing Quality Plan prepared by KMC and approved by LipoScience, which defines the procedures, practices and requirements for the manufacture of the Instrument by KMC. 
 1.20 “Statements” shall have the meaning set forth in Section 10.2 hereof. 
 1.21 “TDP” means the technical data package for the Instrument which includes, without limitation, detail mechanical drawings, assembly drawings, component specification drawings, bill of
materials, schematic and assembly drawings, specifications relating to all of the foregoing, and the ATP, which TDP shall be treated as confidential and proprietary information.by both parties hereto. The TDP shall be owned by LipoScience.

  
 [***] = Certain information on this page, marked
by brackets, has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 2 

 1.22 “Term” means the Initial Term and any extension of the Initial Term
pursuant to Section 13 hereof. 
 1.23 “Unit Sale Price” shall have the meaning set forth in
Section 8.1 hereof. 
 1.24 “Work Request” means a standard KMC document proposing changes, or additions
of work scope to the then existing agreed upon scope of services and work to be performed by KMC. A Work Request will state the reason or basis of the request, an estimate of the anticipated costs associated with such change and an estimate of the
impact on the schedule and the Unit Sale Price. 
 1.24 “Work Product” shall have the meaning set forth in
Section 14.1 of the Development Agreement. 
  

	 	2.	EXCLUSIVITY 

 2.1.
Exclusivity. LipoScience and its Affiliates shall, directly and indirectly, throughout the Term purchase all of their United States’ requirements for the Instrument exclusively from KMC, and KMC shall produce for and sell to LipoScience
and its Affiliates all of their United States’ requirements for the Instrument, all on the terms and conditions of this Agreement. [***] shall have the [***] to [***] to the extent that [***]. Any [***] with respect to such [***] of [***] shall
be at [***] expense and, to the extent [***] or [***] would be [***] to such [***], shall be [***] to such [***] with [***]. In the event [***] is unable to [***] in accordance with the [***] set forth in the [***] for a period of [***] and such
[***] is due to [***], then [***] under this Section. 
  

	 	3.	REGULATORY RESPONSIBILITY 

3.1 LipoScience Regulatory Responsibility. LipoScience shall be responsible for all submissions in connection with, and for
obtaining, all advisable or necessary regulatory approvals to develop, manufacture, market, distribute and sell the Instrument. LipoScience shall also be responsible for all follow-up communications and actions with regulatory agencies
related to the development, manufacture, marketing, distribution and sale of the Instrument, including, but not limited to, compliance with any export regulations, device tracking requirements and medical device reporting. KMC shall assist and
support these efforts related to the Instrument as reasonably required by LipoScience and at LipoScience’s expense, and shall permit as part of its support efforts any applicable regulatory authority to inspect the KMC manufacturing facility as
it may relate to the Instrument or the services provided by KMC hereunder and as required under applicable law or regulation. 

3.2 KMC Regulatory Responsibility. KMC agrees that it shall, at all times during the term of this Agreement, maintain (i) an
FDA and ISO registered medical device manufacturing facility, in compliance with applicable QSR regulations; (ii) all records related to 
  

[***] = Certain information on this page, marked by brackets, has been omitted and filed separately with the Securities and 

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 3 

 
the Instrument as required by applicable United States law and regulation; and (iii) otherwise comply in all material respects with applicable FDA, ISO and QSR laws and regulations with
respect to the manufacture of the Instrument under this Agreement. 
  

	 	4.	TOOLING AND TEST EQUIPMENT 

KMC will purchase, with LipoScience’s approval and at LipoScience’s expense in accordance with Section 10.1, or LipoScience
will supply at its expense, all necessary tooling and test equipment for the build, test and delivery of the Instruments. All such tooling and test equipment paid for (or supplied) by LipoScience in accordance with the provisions of this Agreement
shall remain the property of LipoScience. KMC shall safeguard and maintain such tooling and test equipment in the same manner as it does its own tooling and equipment, but not less than a reasonable manner taking into consideration the nature of the
equipment, provided that LipoScience shall be responsible for payment of all maintenance beyond ordinary and routine maintenance and for refurbishment and/or replacement of such tooling and test equipment, unless such refurbishment and replacement
of any tooling and test equipment is due to the negligence or intentional misconduct of KMC. All tooling and test equipment developed or owned by KMC prior to the Effective Date and all tooling and test equipment not paid for (or supplied) by
LipoScience shall remain the property of KMC. 
  

	 	5.	PRODUCTION OF INSTRUMENTS 

5.1 Production of Instruments. Upon release of the final TDP and receipt of the Purchase Orders (as defined in Section 6) for
the Instruments from LipoScience which are accepted in accordance with Section 6.2 hereof, KMC will build, test, label and ship the Instruments in accordance with applicable manufacturing quality plan and the TDP. 

5.2 Acceptance Testing Procedure. Instruments manufactured by KMC shall be subjected to the ATP prior to shipment, and shall be
deemed accepted by LipoScience upon meeting the requirements of the ATP, as confirmed by KMC’s written certification provided to LipoScience. Title to the Instruments, and risk of loss thereof, shall remain with KMC for so long as KMC is in
possession of the Instruments, and shall transfer to LipoScience upon shipment to (i) LipoScience, (ii) LipoScience’s designated customer, or (iii) a storage facility designated by LipoScience. 

5.3 Materials. LipoScience will supply to KMC at LipoScience’s expense all reagent and disposable materials necessary to
perform the ATP. 
 5.4 Instrument Markings. During the term of this Agreement, KMC shall attach or affix to the
Instruments in a manner and as directed by LipoScience such trademarks, tradenames and logos, and patent legends as LipoScience may designate from time to time (collectively, the “Marks”), all of which LipoScience shall be
responsible for assuring meet the representations and warranties of Section 15. 

  
 4 

 5.5 Primary Contacts. KMC and LipoScience shall each identify an individual who has
the primary responsibility for maintaining contact and communication with the other with regard to this Agreement. 
 5.6
Post-Production Services. Subject to the parties negotiating a mutually agreeable support services agreement, KMC shall provide post-production services in support of the Instruments. These services may include, without limitation:
procurement and production of spare parts and/or sub-assemblies, management of spare parts/sub-assembly inventory (including shipments to field service sites), development of test equipment and procedures for testing of spare parts/sub-assemblies
and/or post-warranty repair and refurbishment services. The parties shall negotiate a separate support services agreement to cover any such support services. 
  

	 	6.	PURCHASE ORDERS 

 6.1
Purchase Orders. Subject to Section 8 hereof, LipoScience shall submit written purchase orders by registered mail, facsimile or email, addressed to the attention of the KMC Business Development Department. Each purchase order (a
“Purchase Order”) will contain an express reference to this Agreement and will state (i) the desired quantity of units of the applicable Instrument(s) to be produced under such Purchase Order, and the Unit Sale Price for such
Instrument determined in accordance with Section 8 hereof; and (ii) the requested shipping schedule, which shall commence no earlier than the longest lead time of any material set forth on Schedule 1 attached hereto [***], as Schedule 1
may be modified by the parties in writing from time to time. With the exception of such quantity, Unit Sale Price and completion schedule, all other terms and conditions of any Purchase Order shall be void and of no force or effect. 

6.2 KMC Review of Purchase Orders. KMC will provide to LipoScience a written response to each Purchase Order within [***] Business
Days of KMC’s receipt of such Purchase Order, indicating either that the above terms of the Purchase Order respecting quantity, shipping schedule and shipping instructions are acceptable as stated, or setting forth necessary adjustments. If KMC
fails to respond to LipoScience within said [***] Business Days, the Purchase Order shall be deemed accepted by KMC as issued by LipoScience with respect to the quantity(ies), Unit Transfer Price(s) and completion date(s) set forth therein.
Likewise, if LipoScience fails to respond to KMC’s written response within [***] Business Days of LipoScience’s receipt of such written response, then the modifications to the Purchase Order set forth in such KMC written response shall be
deemed accepted by LipoScience. 
 6.3 Production Delays. In the event KMC’s production activities under a Purchase
Order are interrupted and/or delayed for any continuous period in excess of [***] calendar days due to a request of LipoScience or the failure by LipoScience to fulfill its obligations under this Agreement, then KMC reserves the right to immediately
invoice LipoScience, [***], for all reasonable expenses incurred by KMC as a direct result of such delay or interruption. [***] means the [***] of [***] and [***] for the [***] as set forth in [***]. [***] shall [***] with [***] along with any [***]
under this Section 6.3. KMC will use reasonable efforts to avoid and/or minimize such expenses, by using reasonable efforts to reallocate internal resources and attempting to negotiate alternative arrangements with outside material suppliers.

  
 [***] = Certain information on this page, marked
by brackets, has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 5 

	 	7.	RESERVED 

  

	 	8.	UNIT SALE PRICE FOR THE INSTRUMENT 

 8.1 Unit Sale Price. The unit sale price for each Instrument will be determined on a Purchase Order-by-Purchase Order basis and shall be based on the pricing formula set forth on Schedule 2
attached to this Agreement (the “Unit Sale Price”) for the Instrument. The initial Unit Sale Price shall be established by KMC upon release of the final TDP and shall be subject to future adjustments pursuant to application of the
pricing formula as set forth on Schedule 2. Prior to LipoScience’s submission of each Purchase Order, LipoScience shall inform KMC of the number of units of each Instrument that LipoScience proposes to order. Upon request by LipoScience, KMC
shall within [***] days thereafter obtain vendor quotes for the applicable quantity of Instruments and provide to LipoScience the Unit Sale Price for that number of units. Upon LipoScience’s final determination of the number of units of each
Instrument that LipoScience proposes to specify in its Purchase Order, the parties shall calculate and mutually agree upon the Unit Sale Price(s) of such Instrument(s). 
 8.2 Adjustments to Unit Sale Price. 
 (a) Increase in
Cost of Materials. In the event the cost of materials increases as a result of a delay or interruption in KMC’s production activities due to a request of LipoScience or the failure of LipoScience to fulfill its obligations under this
Agreement, the then Unit Sale Price shall be increased to reflect such increase in cost of materials. 
 (b)
Unrealized Labor Efficiencies. The parties acknowledge and agree that the Unit Sale Price takes into account the cost of labor for the continuous production of units of the Instrument. To the extent less than such agreed upon units of the
Instrument are produced or such minimum run-rate is interrupted due to the request of LipoScience or the failure of LipoScience to fulfill its obligations under this Agreement, the then Unit Sale Price shall be adjusted by KMC to reflect the
negative impact on the actual labor costs caused by such change. 
 (c) Decrease in Cost of Materials. In
the event the cost of raw materials is decreased based on action initiated by LipoScience, the then Unit Sale Price shall be decreased by KMC by an amount equal to [***] of the reduction in the cost of raw materials plus applicable overhead. In the
event the cost of raw materials is decreased based on action initiated by KMC, the then Unit Sale Price shall be decreased by [***] of the reduction in the cost of raw materials plus [***]. 

8.3 Adjustments to Unit Sale Price. Commencing with [***], KMC shall have the right to adjust the then Unit Sale Price to reflect
[***] increases in its labor costs effective upon not less than [***] days’ prior written notice to LipoScience. 
  

[***] = Certain information on this page, marked by brackets, has been omitted and filed separately with the Securities and 

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 6 

 8.4 Sale of Instruments to Varian, Inc. and its Affiliates. During the Term of this
Agreement, Varian, Inc. and its Affiliates (collectively, the “Varian Parties”) shall have the option to purchase Instruments and spare parts from KMC on terms that taken as a whole are no less favorable as set forth in this Agreement and
the Spare Parts Agreement, dated the date hereof between the parties. Notwithstanding the foregoing, the limitation of liability and security provisions for the agreements between Varian and KMC shall be mutually agreed to at such time and
shall not be subject to the preceding sentence. 
  

	 	9.	WORK SCOPE CHANGES 

 9.1
Work Scope Changes. Either LipoScience or KMC may, from time to time, propose a change in, or an addition to, the work scope in accordance with this Section. Such proposed change or addition may be a change in the TDP or additional work that
is required or recommended to satisfy the overall goals and requirements of LipoScience. 
 9.2 Process for Work Scope
Changes. If LipoScience proposes such change or elects to proceed with consideration of any proposed change by KMC, KMC will prepare and submit to LipoScience a written Work Request. After its receipt of the Work Request, LipoScience, in its
sole discretion, will determine whether or not to approve the Work Request. If LipoScience determines to proceed with the changes detailed in the Work Request, then within ten (l0) Business Days after its receipt of the Work Request, LipoScience
will notify KMC of that determination by signing and returning to KMC the subject Work Request. Failure to respond to KMC within such ten (10) Business Days shall constitute a rejection of the Work Request. KMC will implement changes approved
by LipoScience in writing in accordance with the Work Request and the provisions of Section 9.3 below. All changes to the TDP will be effected by an ECO approved by both parties in writing. 

9.3 Invoicing for Services Rendered Under Work Request. Unless otherwise stated on the Work Request, KMC will submit invoices to
LipoScience on a monthly basis for actual expenses incurred, and for services rendered by KMC, in implementing an approved Work Request. If the Work Request results in a change in the then Unit Sale Price as agreed by both parties, once the change
has been implemented, all subsequent invoices issued by KMC will reflect the amended Unit Sale Price. 
  

	 	10.	INVOICING 

 10.1
Invoicing. KMC shall invoice LipoScience for the Instruments manufactured hereunder upon successfully completing the ATP, at the then Unit Sale Price. 
 10.2 Security. (i) No later than the twentieth (20th) of each month commencing on the Effective Date of this Agreement, LipoScience shall provide KMC with copies of the following
unaudited LipoScience financial documents (collectively, the “Statements”): 
 (a) income statements; 

(b) balance sheet; and 
 (c) cash flow statement. 

  
 7 

 Each monthly set of Statements shall be provided with a report reflecting results of LipoScience’s
operations for the previous month and summary year-to-date results, as applicable for each Statement. 
 In the event, in
KMC’s reasonable discretion, LipoScience’s unrestricted cash balance (which cash balance may include readily marketable securities) for the preceding month is less than [***], LipoScience shall immediately deposit (without KMC being
required to take any action demanding such deposit) the Materials Commitment Amount. The “Material Commitment Amount” will be the monetary total of all [***] that [***] with respect to the [***]. Such Material Commitment Amount
shall be deposited in immediately available funds to the bank indicated by KMC for payment below. Immediately after the occurrence of such event, all KMC invoices shall be due in full (except for amounts disputed in good faith), within [***] days of
the date of such invoices. 
  

			
	Deposit Bank:	  	Bank of America
		  	P.O. Box 4850
		  	Boston, MA 02212-4850

 If LipoScience fails to promptly comply with any obligation under these Sections 10.2 and/or 10.3, KMC
shall provide [***] calendar day’s written notice to LipoScience of such failure to comply, and LipoScience shall fully comply within such [***] days notice. If LipoScience fails to comply within such [***] day period, such compliance shall be
deemed a material breach of this Agreement, and, without limiting any of KMC’s other rights and remedies, KMC shall not be obligated to provide any further services under this Agreement until LipoScience shall have complied in full. 

(ii) LipoScience represents to KMC that the Statements to be provided to KMC in accordance with the requirements of Section 10.2(i)
will fairly present the financial condition and results of operations and cash flow of LipoScience as at the respective dates of and for the periods referred to in such Statements, all in accordance with GAAP; the Statements will reflect the
consistent application of such accounting principles throughout the periods involved; and, to the extent for any period (monthly or year to date) set forth in Section 10.2(i) LipoScience provides financial statements to its investors, such
Statements provided to KMC shall be the same financial statements provided to its investors. 
 10.3 Payment. All
undisputed items on an invoice shall be paid by LipoScience, in full, within [***] calendar days of the date of invoice. Failure to make full payment of such undisputed items on KMC invoices within the [***] day period provided in this Agreement
[***] shall constitute a material breach by LipoScience [***]. Furthermore, KMC may assess LipoScience interest at the rate of one and one-half percent (1 l/2%) per month or the maximum rate allowed by applicable law, whichever is lower, on any past
due amount, together with its costs of collection (including, without limitation, attorneys’ fees and expenses). All invoices shall be payable to KMC in Dollars to a bank in the United States designated by KMC. 

10.4 Disputed Invoices. In the event LipoScience desires to dispute in good faith any invoice, or item under any invoice,
LipoScience will, within fifteen (15) days of the receipt of the given invoice, provide KMC with a written notice setting forth the details of the disputed invoice or item and the amount in question. LipoScience will timely pay to KMC the

  
 [***] = Certain information on this page, marked
by brackets, has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 8 

 
amount of any such invoice not in dispute. The parties will work together, in good faith, to resolve such dispute within thirty (30) days after such notice of dispute is sent.
LipoScience’s failure to pay an invoice or item of an invoice that it disputes in good faith shall not constitute a material breach under this Agreement. If, notwithstanding such efforts, the parties are unable to resolve a dispute within
[***], the parties shall submit the dispute to binding arbitration before a single arbitrator mutually agreeable to the parties (provided, however, that if the parties are unable to mutually agree upon such an arbitrator within [***] calendar days
of the commencement of an arbitration proceeding, then such arbitrator shall be selected by the American Arbitration Association in accordance with its then prevailing rules), which arbitration shall be conducted in accordance with the commercial
arbitration rules of the American Arbitration Association, to be held in the AAA’s offices in [***]. The fees and expenses of the arbitrator shall be borne by [***]. In the event the parties have not resolved such dispute within [***] calendar
days after LipoScience has provided such notice of dispute, [***]. 
 10.5 Taxes. LipoScience shall pay all taxes, fees
and duties or other amounts, however designated, including any value added taxes, which are levied or based upon the fees and other amounts charged by KMC to LipoScience under this Agreement; provided that the foregoing shall not obligate
LipoScience to pay any taxes based on the income, gross receipts or property of KMC. 
 10.6 Reimbursement of Travel
Expenses. Upon prior written request by KMC, and approval in writing by LipoScience, LipoScience shall reimburse KMC for all reasonable travel and related expenses incurred by KMC in connection with the performance of this Agreement. KMC shall
provide receipts and/or other reasonable documentation of all such expenses. 
 10.7 Financial Audits Rights. During the
Term of this Agreement and for a period of three (3) years thereafter, upon five (5) Business Days’ prior written notice to KMC, LipoScience may, at its expense, audit through a third party accounting firm, KMC’s financial
records relating to the performance of this Agreement (which records will be kept by KMC for three (3) years following termination of this Agreement), as reasonably deemed necessary by LipoScience to confirm the amounts payable by LipoScience
hereunder. Any such audit will be performed during KMC’s normal business hours; and LipoScience shall use its reasonable efforts not to disrupt KMC’s business operations during such audit. Audits may be conducted pursuant to this Section
no more than two (2) times in any consecutive twelve (12) month period. In the event LipoScience does request an audit pursuant to this Section, the parties shall mutually agree on the third party accounting firm to conduct such audit. The
accounting firm mutually agreed to by the parties shall be required to sign a non-disclosure agreement with KMC prior to conducting any such audit. The cost of any such audit shall be borne by LipoScience, provided, however, that if, such audit
reveals an overpayment of five percent (5%) or more of the amount that should have been paid for the period(s) audited, then KMC shall bear the expense of the audit, and shall promptly refund to LipoScience any amounts overpaid by LipoScience.

  
 [***] = Certain information on this page, marked
by brackets, has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

  
 9 

	 	11.	SHIPMENT & TRANSPORTATION 

 11.1 F.C.A. Point. All prices are F.C.A. (Incoterms 2000) KMC’s plant. LipoScience shall be responsible for the payment of all transportation charges incurred in connection with this
Agreement. 
 11.2 Shipping Instructions. KMC will ship in accordance with LipoScience’s written shipping
instructions, including, LipoScience’s specified mode of transportation and carrier, and if requested by LipoScience, drop shipments to its designated customers. KMC shall pack and ship the Instruments in such containers and packaging and
labeling as set forth in written instructions from LipoScience. In the absence of specific written shipping instructions, KMC reserves the right to ship by the method it, in good faith, deems most appropriate to the LipoScience facility, but KMC
shall provide LipoScience with at least five (5) Business Days’ written notice of its intent to ship the Instruments in the manner it deems most appropriate prior to actual shipment thereof. 

11.3 Damage Claims. All claims for loss or breakage and damage, whether concealed or obvious, must be made to the carrier by
LipoScience within a reasonable time after receipt of the shipment, but in no event shall KMC be responsible for any such loss, breakage or damage, unless due to KMC’s negligence or willful misconduct, or KMC’s failure to adhere to any
specific packing or shipping instructions provided by LipoScience. 
  

	 	12.	WARRANTY OF KMC 

 12.1
Warranty. KMC warrants to LipoScience that the Instruments manufactured hereunder will be free, under normal use and maintenance, from defects in KMC material and workmanship (the “KMC Warranty”) for [***] (the
“Warranty Period”). KMC shall have no liability under the KMC Warranty for claims arising (in whole or in part) from any of the following: incorrect use, misuse, faulty maintenance, or improper storage of an Instrument. The KMC
Warranty specifically excludes: any materials provided by LipoScience from a third party vendor (a “LipoScience Vendor”), customer furnished, or customer directed materials from a supplier not approved by KMC’s quality
organization, unless such materials have been damaged or mishandled by KMC in the manufacturing process. The KMC Warranty is voided with respect to any Instrument that has been altered, repaired (successfully or not) or had parts replacement by any
party other than KMC, LipoScience or a KMC or LipoScience trained service representative. The KMC Warranty does not cover damages due to fire, explosion, power irregularities, power surges, acts of God or nature, including earthquakes, rain, floods
or lightening, or any other cause not wholly and directly attributable to KMC. 
 12.2 LipoScience Software. The parties
acknowledge and agree that the KMC Warranty specifically excludes any and all liability with respect to any LipoScience Software, regardless of the fact that such software may be incorporated into the Instrument, and/or such software’s
functionality within the Instrument. 
 12.3 Repair or Replace. As LipoScience’s sole and exclusive remedy for any
breaches of the KMC Warranty, KMC will, at KMC’s option, repair or replace without charge, 
  
 [***] = Certain information on this page, marked by brackets, has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 10 

 
any Instrument manufactured by it, which is found by KMC to be so defective; provided, however, that (a) the Instrument is returned in accordance with KMC’s Return
Material Authorization (“RMA”) process, (b) the Instrument, subassembly or component involved is returned by transportation designated by KMC to a location designated by KMC, and at the cost of KMC, and (c) KMC is notified
by LipoScience in writing of the defect within thirty (30) days of the expiration of the Warranty Period set forth in Section 12.1 hereof. 
 12.4 Disclaimer. OTHER THAN THE KMC WARRANTY SPECIFIED IN SECTION 12.1 ABOVE, KMC MAKES NO OTHER WARRANTIES OF ANY KIND WHATSOEVER, EXPRESS OR IMPLIED, WITH RESPECT TO THE INSTRUMENT,
GOODS OR SERVICES TO BE PROVIDED HEREUNDER, AND ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE HEREBY EXPRESSLY DISCLAIMED BY KMC AND EXCLUDED FROM THE TERMS OF THIS AGREEMENT. 

 

	 	13.	TERM AND TERMINATION 

13.1 Term of Agreement. This Agreement will commence as of the Effective Date and, unless sooner terminated as herein provided,
will continue in effect for a period of three (3) years commencing on the date of KMC’s shipment hereunder of the first unit of the Instrument or delivery of the thirtieth (30) unit of the Instrument, whichever is later (the “Initial
Term”). The Initial Term shall automatically extend for additional one (1) year periods unless either party provides the other party with written notice of termination not later than ninety (90) calendar days prior the end of the Initial
Term or any such one (1) year extension. 
 13.2 Termination by Either Party. This Agreement may be terminated at any
time by notice in writing to the other party upon the occurrence of one or more of the following events: 
 (a)
In the event of a material breach hereunder, then the non-breaching party may terminate this Agreement upon not less than [***] calendar days prior written notice, setting forth the alleged breach, unless the breach is cured prior to the expiration
of such notice period. 
 (b) In the event that LipoScience permanently discontinues the marketing of the
Instrument, LipoScience shall have the right to terminate this Agreement upon not less than [***] calendar days prior written notice to KMC; provided, however, if production of the Instrument, or marketing, distribution or sale of the
Instrument, is reinstated by LipoScience within [***] months thereafter, LipoScience shall provide KMC with written notice of such determination and KMC shall have the option and right to have this Agreement reinstated. If KMC shall elect to so
reinstate this Agreement after such termination, then the Term shall automatically be extended by the amount of time for which this Agreement was terminated. 
 (c) If either party shall file a petition in bankruptcy, or shall be adjudicated bankrupt, or shall take advantage of the insolvency law of any state or country, or shall make an assignment for the
benefit of creditors, or shall have a receiver, trustee or other court officer appointed for its property, then the other party may terminate this Agreement upon written notice to the other. 
  
 [***] = Certain information on this page, marked by brackets, has been omitted and filed separately with the
Securities and 
 Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 11 

  

 13.3 Termination by Either Party Upon a Change of Control. In the event that
either KMC or LipoScience experiences a Change of Control (as hereinafter defined) during the Term of this Agreement, then either party may, within [***] days of such Change of Control (and upon [***] written notice to the other party), terminate
this Agreement, whereupon there shall be no further obligations of either party to the other (except that the provisions set forth in Section 35 shall survive). For purposes of this Agreement, a “Change of Control” is defined
to mean a merger, consolidation, corporate reorganization or any transaction in which all or substantially all of the assets or stock of KMC or LipoScience are sold, leased, transferred or otherwise disposed of (other than a mere reincorporation
transaction or one in which the holders of capital stock of KMC or LipoScience immediately prior to such merger, consolidation, corporate reorganization or transaction continue to hold at least a majority of the voting power of the surviving
corporation). 
 13.4 Termination by KMC. In the event KMC’s production activities under a Purchase Order are
interrupted and/or delayed due to the request of LipoScience, or the failure of LipoScience to perform its obligations under this Agreement, for any continuous period in excess of [***] calendar days, then KMC shall have the right to terminate this
Agreement upon [***] days’ written notice to LipoScience. 
 13.5 Obligations Upon Termination. 

(a) Neither termination nor expiration of this Agreement shall release any party from fulfilling any obligations which it may have
incurred prior to any such termination or expiration. In the event of any termination of this Agreement, unless otherwise directed by LipoScience (in the event of termination hereunder by LipoScience) or unless such termination is by KMC pursuant to
Section 13.2(a) hereof, KMC will complete the outstanding Purchase Order activity. 
 (b) In addition to any other amounts
due under this Agreement, LipoScience shall pay KMC for all reasonable expenses incurred by KMC in performance of this Agreement due to non-cancelable material and labor commitments made by KMC prior to receipt by KMC of a written notice of
termination from LipoScience or KMC’s issuance of a written notice of termination to LipoScience, provided that KMC shall provide to LipoScience all receipts, invoices and other reasonable evidence of such costs and expenses as reasonably
requested by LipoScience. These expenses may include, but are not limited to, completed but uncompensated production labor hours expended, inventory and work-in-process, and materials ordered and not returnable or subject to cancellation, actual
cancellation charges, restocking fees and other similar charges incurred by KMC, all to the extent that such costs and expenses are consistent with the Purchase Commitment provided to KMC and at KMC’s then current sell rates less advance
payments, if any, made by LipoScience to KMC toward such expenses. KMC will use reasonable efforts to minimize such termination expenses. 
  

[***] = Certain information on this page, marked by brackets, has been omitted and filed separately with the Securities and 

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 12 

 (c) If LipoScience terminates this Agreement as a result of a breach by KMC of any of
Sections 2, 3.2, 5.1 or 5.2 of this Agreement, then KMC shall, at KMC’s own expense, cooperate with the transfer of the TDP and any LipoScience Work Product and specific know-how related to the manufacture of the Instruments to
LipoScience’s new manufacturing partner. Any such cooperation by KMC shall be subject first to any new manufacturing partner entering into a reasonable confidential nondisclosure agreement with KMC with respect to KMC’s confidential and
proprietary information. The rights of LipoScience set forth in the Section shall be in addition to any other rights and privileges that LipoScience may be entitled to under law or equity. 

(d) Upon any termination or expiration of this Agreement, KMC shall promptly deliver to LipoScience the TDP, such other materials paid
for by LipoScience, unless LipoScience requests that any such materials be destroyed, and any specific know-how related to the manufacture of the Instruments to LipoScience’s new manufacturing partner, at LipoScience’s expense. 

 

	 	14.	INTELLECTUAL PROPERTY 

14.1 No New Work Product or Intellectual Property. The parties agree that no Intellectual Property is expected to be developed
under this Agreement. All Work Product owned by LipoScience pursuant to the terms of the Development Agreement shall remain the Work Product of LipoScience, and all Work Product owned by KMC pursuant to the terms of the Development Agreement shall
remain the Work Product of KMC. Each of the parties respective other Intellectual Property shall remain its own property, and except as set forth in Section 15 below, nothing in this Agreement shall be construed as granting any license or
assignment, by implication, estoppel or otherwise, to either party to make, have made, use, or sell any Intellectual Property of the other party. In the event that any new Intellectual Property is developed with respect to the Instrument by KMC
during the performance of its services under this Agreement, KMC agrees to assign such intellectual property rights in and to such Intellectual Property to LipoScience, and agrees to cooperate at LipoScience’s expense in LipoScience’s
efforts to effect, perfect, maintain and evidence such assignment. 
  

	 	15.	INFRINGEMENT 

 15.1
Grant of Limited License. LipoScience grants KMC a limited, revocable, non-exclusive, non-transferable, and non-sublicenseable license, under which KMC may use the Marks solely in connection with KMC’s production of the Instruments and
the labels and packaging therefor. LipoScience reserves all rights in the Marks not expressly granted in this Agreement. 
 15.2
Infringement. Except with respect to the [***], LipoScience represents and warrants that neither it, nor any third parties retained by it in connection herewith (excluding KMC) shall provide any materials, components, designs, trademarks,
trade names, logos, information or documentation to be used or incorporated into the Instruments that violate the patent, copyrights, trade secrets or other personal or proprietary rights of a third party. Except with respect to the [***],
LipoScience represents and warrants to KMC that it is the sole and 
  
 [***] = Certain information on this page, marked by brackets, has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 13 

 
exclusive owner of, and has the sole and exclusive right to license, all the Marks as licensed hereunder and has obtained all permissions necessary for KMC to lawfully perform its obligations
under this Agreement with respect to the Marks. 
 15.3 [***]. In addition to the indemnification obligations of LipoScience in
Section 18.1 below, LipoScience agrees to indemnify, defend and hold harmless KMC, its Affiliates, and their officers, directors, employees, and agents (the [***]) from and against any and all losses, costs, damages, liabilities and expenses of
any kind whatsoever payable to third parties (including all reasonable attorneys’ fees and court costs) incurred by the [***] in connection with any and all suits, investigations, claims or demands of third parties (collectively, the [***])
with respect to the [***]. In the event any [***] is asserted against a [***] for which LipoScience may be required to indemnify such [***] under this provision, KMC shall give LipoScience prompt written notice of same. KMC shall cooperate with
LipoScience, upon LipoScience’s reasonable request and at LipoScience’s cost and expense, in the defense of any such Claim. LipoScience shall have the sole right to defend and/or settle such a Claim, including selecting counsel of its
choice, reasonably acceptable to KMC, provided that, in the event of settlement, the settlement is for monetary damages only and is conditioned upon a full and unconditional release of the [***]. 

 

	 	16.	NON-SOLICITATION 

 During
the Term and for a period of [***] thereafter, neither KMC nor LipoScience shall solicit directly or indirectly (whether for its own account or for the account of any other person or entity) for employment any employees of the other. The parties
acknowledge and agree that nothing herein shall prohibit a party from hiring anyone who responds to an employment advertisement placed in a publication of general circulation, including, without limitation, the internet. 

 

	 	17.	INSURANCE COVERAGE 

 17.1
Insurance Obligation of KMC. KMC maintains, and shall maintain in good standing throughout the Term, comprehensive general liability insurance in an amount of at least $[***] per occurrence and in the aggregate. Upon written request by
LipoScience, KMC shall deliver to LipoScience a certificate of insurance verifying such insurance coverage. 
 17.2 Insurance
Obligation of LipoScience. LipoScience maintains, and shall maintain in good standing throughout the Term, comprehensive general liability insurance in an amount of at least $[***] per occurrence and in the aggregate. Upon written request by
KMC, LipoScience shall deliver to KMC a certificate of insurance verifying such insurance coverage. 
  

	 	18.	INDEMNITY 

 18.1 By
LipoScience. (a) LipoScience agrees to indemnify, defend and hold harmless KMC and its officers, directors, employees, customers, distributors and agents (the “KMC Indemnified Parties”) from and against any and all losses,
costs, damages, liabilities and expenses of any kind whatsoever claimed by and payable to third parties (including all 
  

[***] = Certain information on this page, marked by brackets, has been omitted and filed separately with the Securities and 

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 14 

 
reasonable attorneys’ fees and court costs) (collectively, “Damages”) incurred by the KMC Indemnified Parties in connection with any and all suits, investigations, claims or
demands of third parties (collectively, “Claims”) arising from any Instrument or the services provided by KMC hereunder, except to the extent that same results from the negligence, negligent omission or willful misconduct of KMC, or the
breach of this Agreement by KMC. In the event any Claim is asserted or filed against a KMC Indemnified Party for which LipoScience may be required to indemnify such KMC Indemnified Party under this provision, KMC shall give LipoScience prompt
written notice of same. KMC shall cooperate with LipoScience, upon LipoScience’s reasonable request and at LipoScience’s cost and expense, in the defense of any such claim. LipoScience shall have the sole right to defend and/or settle such
a claim, including selecting counsel of its choice, reasonably acceptable to KMC, provided that KMC shall not be bound by any settlement or compromise of any Claim without its prior written consent. 

18.2 By KMC. KMC agrees to indemnify, defend and hold harmless LipoScience and its officers, directors, employees, customers,
distributors and agents (the “LipoScience Indemnified Parties”) from and against any and all Damages incurred by the LipoScience Indemnified Parties in connection with any and all Claims arising out of or in any way connected with or the
production services provided by KMC hereunder, provided the same results from the negligence, negligent omission or willful misconduct of KMC, or the breach of this Agreement by KMC. In the event any Claim is asserted or filed against any
LipoScience Indemnitee for which KMC may be required to indemnify LipoScience under this provision, LipoScience shall give KMC prompt written notice of same and shall cooperate with KMC, upon KMC’s reasonable request and at KMC’s cost and
expense, in the defense of any such claim. KMC shall have the sole right to defend and/or settle such a claim, including selecting counsel of its choice, reasonably acceptable to LipoScience, provided that LipoScience shall not be bound by any
settlement or compromise of any Claim without its prior written consent. 
  

	 	19.	LIMITATION OF LIABILITY 

19.1 WAIVER OF DAMAGES, LIMITATION ON LIABILITY. [***], NEITHER LIPOSCIENCE NOR KMC SHALL BE LIABLE IN CONTRACT,
TORT OR OTHERWISE, TO THE OTHER FOR ANY INCIDENTAL, CONSEQUENTIAL, INDIRECT, EXEMPLARY, PUNITIVE OR SPECIAL DAMAGES OF ANY KIND OR NATURE, INCLUDING WITHOUT LIMITATION, LOST REVENUES, LOST PROFITS, DELAY OR LOSS OF BUSINESS ARISING OUT OF OR
RELATING TO THIS AGREEMENT OR THE BREACH THEREOF, WHETHER OR NOT LIPOSCIENCE OR KMC WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGE. EXCEPT WITH RESPECT TO LIPOSCIENCE’S OBLIGATIONS UNDER SECTION 15.3, NEITHER PARTY’S LIABILITY ON ANY CLAIM
OF ANY KIND, INCLUDING NEGLIGENCE, FOR ANY LOSS OR DAMAGE ARISING OUT OF, CONNECTED WITH, OR RESULTING FROM THIS AGREEMENT OR PERFORMANCE OR BREACH THEREOF, SHALL IN ANY SINGLE CASE, OR IN THE AGGREGATE, EXCEED [***]. IF THE AMOUNTS PAID BY
LIPOSCIENCE TO KMC DURING THE TERM OF THIS AGREEMENT ARE [***], THE LIMITATION OF LIABILITY SET FORTH IN THE PRECEDING SENTENCE SHALL BE [***] IN THE AMOUNT [***]  
  
 [***] = Certain information on this page, marked by brackets, has been omitted and filed separately with the
Securities and 
 Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 15 

 
BY [***] TO [***]. EACH PARTY ACKNOWLEDGES AND AGREES THAT THE FOREGOING LIMITATIONS ON LIABILITY ARE ESSENTIAL ELEMENTS OF THE BASIS OF THE BARGAIN BETWEEN THE PARTIES AND THAT IN
THE ABSENCE OF SUCH LIMITATIONS, THE MATERIAL AND ECONOMIC TERMS OF THIS AGREEMENT WOULD BE SUBSTANTIALLY DIFFERENT. 
  

	 	20.	FORCE MAJEURE 

 Neither
party shall be deemed in default of this Agreement to the extent that performance of its obligations (except for payment obligations), or attempts to cure any breach are delayed or prevented by acts or occurrences beyond the reasonable control of
such party, including without limitation acts of civil or military authorities, any law, order, direction, regulation, ordinance, action, of any governmental authority, embargoes, epidemics, fires, flood, tornadoes, hurricanes, earthquakes,
unusually severe weather conditions, volcanic action, storm, other environmental disturbances, wars, riots, insurrections, civil disturbances, explosions, nuclear accidents, threats or acts of terrorism or similar acts, electrical power surges or
failures, work stoppages or slow downs, acts of God, vandalism, other similar catastrophe; national emergencies, strikes, lockouts, inability to secure products or services of other persons, curtailment of transportation facilities, acts of
transportation carriers, governmental travel advisories or prohibitions, (individually or collectively, a “Force Majeure”), provided that such failure to perform is not caused by the negligence or willful act(s) of the
non-performing party and provided that the party whose performance will be delayed by such events will use (i) its reasonable efforts to notify the other promptly of its becoming aware of the occurrence of such an event, and (ii) all
reasonable efforts to continue to so perform or cure. Such party whose performance has been delayed by an event of force majeure will also provide prompt notice to the other party of the cessation of such event. 

 

	 	21.	ASSIGNMENT 

 This
Agreement shall inure to the benefit of and bind the parties and their respective successors and permitted assigns; provided however, neither party shall have the right to transfer or assign this Agreement or its rights and obligations under this
Agreement to any third party without the other party’s prior written consent, such consent not to be unreasonably withheld or delayed, except that either party may, without the other party’s consent, assign or transfer this Agreement or
any rights hereunder to an entity with which such party engages in a Change of Control transaction. Notwithstanding the foregoing, each party shall nonetheless have the right to terminate this Agreement in the event of a Change of Control pursuant
to the terms and conditions set forth in Section 13.3 herein. 
  

	 	22.	AMENDMENTS 

 No provision
of this Agreement may be amended, modified or otherwise changed, other than by an instrument in writing duly executed on behalf of the parties to this Agreement. 

 
 [***] = Certain information on this page, marked by brackets,
has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  
 16 

	 	23.	ENTIRE AGREEMENT 

 The
Development Agreement, this Agreement and its Attachments, constitute the entire understanding between the parties with respect to the subject matter hereof, and shall supersede and nullify all prior or contemporaneous agreements, whether written or
oral, relating thereto; provided, however, that the parties shall continue to be bound under that certain Mutual Nondisclosure Agreement (the “NDA”) executed by the parties, dated as of November 1, 2004, which continues to be
in full force and effect in accordance with its terms except that its term is hereby amended to be concurrent with the term and any termination of this Agreement. 
  

	 	24.	NOTICES 

 All notices,
demands and requests or other documents to be given hereunder shall be in writing and shall be deemed to have been given for all purposes (a) upon personal delivery, (b) one (1) day after being sent, when sent by professional
overnight courier service from and to locations within the continental United States, (c) five (5) days after posting when sent by registered or certified mail, addressed as set forth below or (d) when sent, if sent by facsimile,
provided that the receipt of successful facsimile transmission is received by the sender and, in each case, addressed to the party at the following address for such party or such other address as is provided by a party to the other in accordance
with this Article: 
  

			
	For LipoScience:	  	LipoScience, Inc.
		  	2500 Sumner Boulevard
		  	Raleigh, NC 27616
		  	Attention: President
		  	Fax No.: [***]
		
	With a copy to:	  	
		  	LipoScience, Inc.
		  	Attention: General Counsel
		  	2500 Sumner Boulevard
		  	Raleigh, NC 27616
		  	Fax No.: [***]
	For KMC:	  	
		  	KMC Systems, Inc.
		  	220 Daniel Webster Highway
		  	Merrimack, NH 03054
		  	Attention: President
		  	Fax No.: [***]
		
	With a copy to:	  	
		  	KMC Systems, Inc.
		  	220 Daniel Webster Highway
		  	Merrimack, New Hampshire 03054
		  	Attention: General Counsel
		  	Fax No.: [***]

  
 [***] = Certain information on
this page, marked by brackets, has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 17 

	 	25.	GOVERNING LAW 

 This
Agreement shall be governed by and construed in accordance with the laws of the State of Delaware applicable to contracts made in and entirely performed in such State, and, therefore, without regard to conflict of laws principles. The parties
acknowledge and agree that the Uniform Computer Information Transaction Act and the United Nations Convention on Contracts for the International Sale of Goods do not and will not apply to this Agreement or the transactions contemplated herein.

  

	 	26.	EMPLOYEES 

 Each
party’s personnel shall serve under the exclusive direction and control of that party and shall not be deemed to be employees or agents of the other party. Each party shall be solely responsible for payments of all such personnel’s
compensation, including wages, benefits, taxes, workers’ compensation, disability, and other insurance and the withholding or deduction of such items to the extent required by applicable law. 

 

	 	27.	RELATIONSHIP OF PARTIES 

The parties to this Agreement are independent contractors and not joint venturers or partners. Neither party shall be deemed to be an
agent of the other party as a result of any transaction under or related to this Agreement. 
  

	 	28.	COMPLIANCE WITH LAWS; ANTI-TERRORISM AND ANTI-CORRUPTION 

 In their performance of this Agreement, the parties shall comply with the provisions of all applicable federal, state, county, and local laws, ordinances, regulations and codes (including procurement of
required permits, licenses or certificates), including, without limitation: 
 (i) laws governing the making of improper
payments; 
 (ii) United States and non-United States export control laws; 

(iii) the United States Foreign Corrupt Practices Act; and 
 (iv) the United States Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (USA Patriot Act) Act of 2001 and U.S. Executive Order 13224.

 The parties agree to notify the other immediately in writing in the event that any of the covenants in this Section cease to
be accurate. Each party agrees to indemnify the other party for, defend against, and hold harmless from, any loss or damage sustained because of the other party’s noncompliance under this Section. 

  
 18 

	 	29.	COMPLIANCE WITH FACILITY RULES 

 The respective agents and employees of the parties, while on the premises of the other, shall comply with all facility rules, regulations and reasonable company standards for security. 

 

	 	30.	WAIVER 

 The failure of
either party to insist upon strict compliance with any of the terms, covenants, or conditions herein shall not be deemed a waiver by such party of such terms, covenants or conditions, nor shall any waiver or relinquishment of any right at any one or
more times be deemed a waiver or relinquishment of such right at any other times, nor shall any single or partial exercise of any right or remedy hereunder preclude any other or a future exercise thereof or the exercise of any other right or remedy
granted hereby or by any related document or by law. 
  

	 	31.	SEVERABILITY 

 The
invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. Any provision declared invalid or unenforceable by a court of competent jurisdiction shall be deemed to be
automatically amended and replaced by a valid and enforceable provision that accomplishes, to the greatest extent possible, the purpose and intent of the original provision, and the remaining terms and conditions of this Agreement shall remain in
full force and effect. 
  

	 	32.	FEES AND EXPENSES 

 Except
as otherwise provided in this Agreement, each of the parties hereto shall pay its own fees and expenses (including, without limitation, the fees of any attorneys, accountants, investment bankers or other representatives and travel expenses) incurred
in connection with this Agreement and the transactions contemplated hereunder, whether or not such transactions are consummated. 
  

	 	33.	CONSTRUCTION 

 The parties
have jointly prepared this Agreement, and it may not be strictly construed against either party. 
  

	 	34.	COUNTERPARTS 

 This
Agreement may be fully executed in one (1) or more counterparts, all of which shall be deemed an original, and taken together shall constitute one and the same instrument. 

 

	 	35.	SURVIVAL 

 Notwithstanding
any termination or expiration of this Agreement, the following sections shall survive: Section 10.7 (Financial Audit Rights – for the period contemplated in such Section), Article 12 (Warranty of KMC – for the period contemplated in
such Article), Section 

  
 19 

 
13.5 (Obligations upon Termination), Article 14 (Intellectual Property), Article 15 (Infringement), Article 16 (Non-Solicitation), Article 18 (Indemnification), Article 19 (Limitation of
Liability), Article 25 (Choice of Law), and Article 35 (Survival). 
 [remainder of page intentionally blank; signature page
follows] 

  
 20 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
above written. 
  

			
	LIPOSCIENCE, INC., a Delaware corporation
		
	By:	 	 /s/ Lucy G. Martindale

	Name:       Lucy G. Martindale
	Title:      CFO

			
	
	KMC SYSTEMS, INC., a Delaware corporation
		
	By:	 	 /s/ Patrick W. McNallen

		 	   Patrick W. McNallen
   President

  

 LIST OF APPENDICES 

 

					
	APPENDIX I	 	Elements of Instruments	 	

 LIST OF SCHEDULES 

 

					
	SCHEDULE 1	 	Material Lead Times	 	
			
	SCHEDULE 2	 	Pricing Formula; Unit Sale Price	 	

  

 *** Text Omitted and Filed Separately 

Confidential Treatment Requested 
 Under 17 CFR §§ 200.80(b)(4) and 230.406 
  

 APPENDIX I 
 TO 
 PRODUCTION AGREEMENT 

Elements of Instruments 
 The LipoScience Numera Analyzer is a multi-assay, clinical laboratory instrument that employs nuclear magnetic resonance spectroscopic detection to quantify multiple analyses in biological fluid
specimens, specifically blood plasma and serum. The current configuration of the Numera Instrument provides a diagnostic evaluation of a patient’s risk for cardiovascular disease and related maladies. This is done by detecting the response of a
patient’s blood sample when placed in a magnetic field and exposed to radio frequency pulses. The resulting NMR LipoProfile provides an improved diagnostic result over traditional Total Cholesterol, HDL, LDL and Triglyceride
measurements. The instrument shall contain features intended to support additional NMR assays as they are developed. 
 The NMR System, Part
Number [***] is partitioned into four major components: 
 [***] 
 The table below denotes the activity and responsibility for supply, assembly and test. 
  

[***] = Certain information on this page has been omitted and filed separately with the Securities and 

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

 *** Text Omitted and Filed Separately 

Confidential Treatment Requested 
 Under 17 CFR §§ 200.80(b)(4) and 230.406 
  

 SCHEDULE 1 
 TO 
 PRODUCTION AGREEMENT 

Material Lead Times 
 [***] 
  

[***] = Certain information on this page has been omitted and filed separately with the Securities and 

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

 *** Text Omitted and Filed Separately 

Confidential Treatment Requested 
 Under 17 CFR §§ 200.80(b)(4) and 230.406 
  

 SCHEDULE 2 
 TO 
 PRODUCTION AGREEMENT 

Pricing Formula; Unit Sale Price 
 The following formula will be used for calculation of the Unit Sale Price to LipoScience: 
 Material Cost = Total Raw Material Cost multiplied by [***] 
 Labor Cost = Total
Direct Labor Cost multiplied by [***] 
 Total Cost = (Material Cost plus Labor Cost) multiplied by [***] 

Unit Sale Price = Total Cost multiplied by [***] 
 For illustrative purposes, the following is an example of the application of the foregoing formula that is based on data from Schedule 1 on the date hereof: 

Instrument Unit Build 

							
	 	  	Purchase Order Quantity
	 	  	[***]	 	[***]	 	[***]
	 Total Raw Material Cost
	  	[***]	 	[***]	 	[***]
	 Total Material Cost = Total Raw Material Cost x [***]
	  	[***]	 	[***]	 	[***]
				
	 Total Direct Labor Cost
	  	[***]	 	[***]	 	[***]
	 Total Labor Cost = Total Direct Labor Cost x [***]
	  	[***]	 	[***]	 	[***]
				
	 Total Cost = (Total Material Cost + Total Labor Cost) x [***]
	  	[***]	 	[***]	 	[***]
				
	 Unit Sale Price = Total Cost x [***]
	  	[***]	 	[***]	 	[***]

 Assumptions: 

	1.	Based on released BOM as of April 30, 2009, as further described on Schedule 1 

	2.	Labor Cost is based on anticipated direct labor rates for 2010 

  

[***] = Certain information on this page has been omitted and filed separately with the Securities and 

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.Exhibit 10.35

 Exhibit 10.35 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested 

Under 17 CFR §§ 200.80(b)(4) and 230.406 
 AGREEMENT 
 This Agreement (“Agreement”) is entered into
by and between Laboratory Corporation of America Holdings, a Delaware corporation having a place of business at 430 South Spring Street, Burlington, North Carolina 27215 (“LabCorp”), and LipoScience, Inc., a Delaware corporation
having a place of business at 2500 Sumner Blvd., Raleigh, NC 27616 (“LipoScience”), effective as of the 8th day of June, 2005 (the “Effective Date”). 

WHEREAS, LipoScience has developed and is marketing the NMR LipoProfile® test, a clinical diagnostic tool; and 

WHEREAS, LabCorp is engaged in the business of providing laboratory testing services; and 

WHEREAS, the purpose of this Agreement is to set forth the terms by which LabCorp will initially have certain tests performed by
LipoScience during Phase One, and then subsequently and subject to LabCorp attainment of a certain number of Test orders, LipoScience and LabCorp will negotiate a license to LabCorp of certain technology and associated intellectual property of
LipoScience so that LabCorp can perform such testing services in its own facilities. 
 NOW, THEREFORE, in consideration
of the mutual covenants exchanged herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, LabCorp and LipoScience hereby agree to be legally bound as follows: 

1. Definitions. For purposes of this Agreement, the terms below shall have the meanings set forth below. Additional terms are defined throughout
the Agreement. 
 “Affiliate” means, with respect to a party to this Agreement, any current or future Entity
which controls, is controlled by, or is under common control with such party. For purposes of this definition only, “control” means direct or indirect ownership of more than fifty percent (50%) of the shares of the subject Entity
entitled to vote in the election of directors (or, in the case of an Entity that is not a corporation, for the election of the corresponding managing authority). Affiliates of LabCorp as of the date of signing this Agreement are listed on Exhibit F.

 “Applicable Service Fee” means (except as provided otherwise in Section 4.2, 4.3 or 4.6): 

a. For Tests performed in 2005, and for Tests performed after 2005 during any calendar month in which Tier 1 Promotion is not provided by
LabCorp: 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

1 

 (i) [***] per Test for any calendar month in which LipoScience receives less than [***]
orders for Tests from LabCorp and its Affiliates; or 
 (ii) [***] per Test for any calendar month in which LipoScience
receives at least [***] orders for Tests from LabCorp and its Affiliates. 
 b. For Tests performed after 2005 during any
calendar month in which Tier 1 Promotion is provided by LabCorp: 
 (i) [***] per Test for any calendar month in which
LipoScience receives less than [***] orders for Tests from LabCorp and its Affiliates; or 
 (ii) [***] per Test for any
calendar month in which LipoScience receives at least [***] orders for Tests from LabCorp and its Affiliates. 

“Baseline LipoScience Tests” means the average number of billable Tests performed for patient care purposes by
LipoScience each calendar month over the nine full calendar months prior to the Effective Date. 
 “Best Faith
Effort Factor” (or “BFE”) with regard to Phase One means the total number of Tests performed by LipoScience for LabCorp during the applicable calendar month divided by an amount equal to the difference of the Baseline LipoScience
Tests minus the number of billable Tests performed for patient care purposes by LipoScience for anyone other than LabCorp during the applicable calendar month. For example, if the total number of Tests performed by LipoScience for LabCorp during a
particular calendar month is 20,000, the Baseline LipoScience Tests is 10,000, and the number of billable Tests performed for patient care purposes by LipoScience for anyone other than LabCorp is 5,000, then the Best Faith Effort Factor is 4 (since
20,000/(10,000-5,000) = 4).  
 “Change of Control” means an event as a result of which the holders of
the outstanding voting securities of LipoScience as of the Effective Date cease to own a majority of the outstanding voting securities of LipoScience. 
 “CLIA” means the Clinical Laboratory Improvement Act and the regulations issued thereunder. 
 “CMS” means Centers for Medicare & Medicaid Services, which is a Federal agency within the U.S. Department of Health and Human Services. 

“Competitor of LabCorp” means a national full service clinical laboratory with annual revenues in excess of [***].

 “Confidential Information” means any confidential information of or concerning a party or its Affiliates.
Without limiting the foregoing and for illustrative purposes only, (i) all Test results and attendant information, nonpublic financial information, pricing, customer 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

2 

 
information, LabCorp SOPs and technical information, and other information furnished or disclosed to LipoScience by LabCorp and its Affiliates in connection with this Agreement shall be
considered Confidential Information of LabCorp and its Affiliates, and (ii) all nonpublic information relating to the Test, including without limitation, all of LipoScience’s protocols and standards for performance of the Test and the
number of Tests performed by LipoScience (but excluding information belonging to or developed by LabCorp during Phase One of the Agreement) shall be considered Confidential Information of LipoScience. 

“Current Average Reimbursement” means an amount equal to the payments actually received by LabCorp and its
Affiliates from third parties and patients with respect to Tests billed under the 83716 CPT Code performed during a particular calendar quarter divided by the number of such Tests, regardless of when such payments are received.  

“Current Rate” means the then-applicable reimbursement rate established by CMS for CPT Code 83716. 

“Entity” means a person, corporation, partnership, association, limited liability company, unincorporated organization,
firm, or other entity. 
 “New Rate’ means the then-applicable reimbursement rate to be established by CMS for
the NMR-specific CPT Code. 
 “NMR Average Reimbursement” means an amount equal to the payments actually
received by LabCorp and its Affiliates from third parties and patients with respect to Tests billed under the NMR-specific CPT Code performed during a particular calendar quarter divided by the number of such Tests, regardless of when such payments
are received. 
 “NMR-specific CPT Code” means the CPT code that is assigned to the Test by CMS.

 “Phase One” means the period beginning on the Effective Date and ending upon the earlier of
(i) commencement of Phase Two as specified in Section 3.1, or (ii) termination of this Agreement. 

“Phase Two” has the meaning set forth in Section 3 of this Agreement. 

“Reimbursement Adjustment Factor” (or “RAF”) means for each month the product of [***] times an amount equal
to the New Rate minus the Current Rate; provided, however, that in the event the New Rate is less than the Current Rate, the RAF shall equal zero (0). For example, if the New Rate is [***] and the Current Rate is [***], then the RAF
would be [***] (since [***] x ([***] – [***]) = [***]). 
 “Services” means performance of Tests by
LipoScience for LabCorp and its Affiliates. 
 “Term” means the period beginning on the Effective Date and
ending upon termination of this Agreement. 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

3 

 “Test” means the NMR LipoProfile® test, which is a
cardiovascular diagnostic test that uses nuclear magnetic resonance (NMR) spectroscopy to provide rapid, simultaneous and direct measurement of LDL particle number and size of LDL particles, as well as direct measurement of HDL and VLDL
subclasses. A sample Test report is attached as Exhibit B. 
 “Tier 1 Promotion” shall mean part of
a defined and differentiated national marketing and sales program designed by LabCorp to educate its customers and potential customers, as modified by LabCorp from time to time in its sole discretion, which shall include material sales incentives
for LabCorp’s eligible marketing and sales personnel, in addition to any standard sales incentive plans, and inclusion in a prominent position in sales meetings and in promotional materials provided to physicians. 

“Trademarks” means those trademarks, service marks and applications listed on Exhibit A and used by LipoScience in
connection with the Test. 
 2. Reference Testing Services. 

2.1 Performance of Services. During Phase One (and thereafter if requested by LabCorp), LipoScience agrees to fulfill all
orders received from LabCorp and its Affiliates for Tests to be performed and otherwise provide the Services as requested by LabCorp and its Affiliates.  
 2.2 Process. 
 a. Sample Collection and Reporting of Test Results.
When Tests are ordered, LabCorp’s patient service centers (PSCs) and courier networks will collect and forward samples to LipoScience for performance of the Services and reporting back to LabCorp. All samples will be collected and sent to
LipoScience in accordance with LipoScience’s standard requirements as set forth on Exhibit C (the “Sample Requirements”). LipoScience will use commercially reasonable efforts to report Test results within forty-eight
(48) hours from receipt of the order and applicable sample from LabCorp; provided that such sample has been collected and shipped in accordance with the Sample Requirements. LipoScience shall report the Test results to LabCorp and LabCorp will
report the Test results to the ordering medical provider, unless otherwise required by applicable law or regulation or agreed by the parties. In the event tests other than the Test are ordered (in addition to the Test) on LabCorp’s requisition
form, LabCorp will perform (or otherwise arrange for the performance of) such other tests and send LipoScience the applicable portion of such requisition form and appropriate sample in accordance with the Sample Requirements for performance of the
Services. 
 b. Billing Payors. To the extent consistent with applicable law and existing agreements, LabCorp will
invoice the appropriate payor and assume other billing activities for the Services. To the extent LabCorp is unable, under applicable law or existing agreements, to invoice the appropriate payor and assume other billing activities for the Services
pursuant to the prior sentence, (a) LabCorp shall not be obligated to pay LipoScience an Applicable Service Fee, and 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

4 

 
LipoScience in its sole discretion may bill third parties for results derived from such specimens; (b), LabCorp will use commercially reasonable efforts to provide to LipoScience all appropriate
payor, billing and other information to enable LipoScience to bill the appropriate parties; and (c) the parties agree to cooperate in good faith and make commercially reasonable efforts (including but not limited to modifying existing
agreements) to transition such invoicing and billing activities to LabCorp on a State-by-State or payor-by-payor basis. 
 2.3
Changes. LipoScience shall use commercially reasonable efforts to provide a forty five (45) day prior written notification to LabCorp of any changes to Test methodology, reference ranges, specimen type, interpretive comments or any other
pertinent information relative to Tests performed by LipoScience. 
 2.4 Results. Unless otherwise required under
applicable law or regulation, LipoScience will report all test results to the location and personnel designated by LabCorp. LabCorp and LipoScience shall mutually agree upon the manner of such result transmission. Each of the parties will use
commercially reasonable efforts to develop an interface with LabCorp’s system to allow LabCorp to enter orders and receive results electronically; provided, however, that LipoScience shall not be required under this provision to provide to
LabCorp any software programs, code or portion thereof or to incur any additional expenses related to such efforts. 
 2.5
Utilization Reports. LipoScience will provide LabCorp utilization reports on a monthly basis in hard copy or by electronic mail in a mutually agreed upon format (including without limitation Test volumes and average turn-around time).

 2.6 Adverse Circumstances. LipoScience shall immediately notify LabCorp of any events or circumstances, including, but
not limited to, adverse weather conditions, common carrier delays, illness, breakdowns, accidents, or any other condition which may adversely affect LipoScience’s rendering of Services required under this Agreement. 

2.7 Waste Disposal. LipoScience shall be solely responsible for the disposal of any medical or other waste generated in
performance of the Services at LipoScience’s facilities. 
 2.8 Compliance with Laws. LipoScience agrees to comply
with all applicable laws and regulations related to the Services and any commercially reasonable specific requirements of managed care plans or other third party payors communicated by LabCorp to LipoScience from time to time. LabCorp will comply
with all applicable laws and regulations related to the collection and mailing of all specimens and samples to LipoScience for performance of the Services. 
 2.9 Non-Discrimination. All Services provided by LipoScience hereunder shall be in compliance with all applicable federal and state laws prohibiting discrimination on the basis of race, color,
religion, sex, national origin, handicap, veteran status or protected status. 
 2.10 Disclosure Requirements. If the
Services to be provided by LipoScience hereunder are subject to the disclosure requirements of 42 U.S.C. 1395x (v) (1) (I), LipoScience, shall until 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

5 

 
expiration of four (4) years from the termination of the Agreement, make available, upon written request to the Secretary of Health and Human Services, or upon request to the Comptroller
General, or any of their duly authorized representatives, a copy of this Agreement and the books, documents and records of LipoScience that are necessary to certify the nature and extent of the costs incurred under this Agreement through a
subcontractor with a value or cost of $10,000.00 or more over a twelve (12) month period. 
 2.11 Medicare + Choice
Provisions. LipoScience and LabCorp hereby agree that the provisions on Exhibit D are applicable to Services provided to Medicare + Choice Members. 
 2.12 Inspection Rights. Upon reasonable written notice and during normal business hours, LabCorp shall have the right to inspect LipoScience’s testing facilities for the purpose of verifying
the existence of appropriate quality systems as required under applicable law or regulation or on some other reasonable basis. 

3. Phase Two. 
 3.1 Description of Phase Two. The parties will negotiate in good faith a license agreement whereby LabCorp would be entitled to use certain intellectual property of LipoScience relating to the Test
in order to perform the Test at LabCorp’s facilities (“Phase Two”), subject to the payment of certain royalties to LipoScience and other terms as mutually agreed upon by the parties. Unless otherwise agreed by the parties, neither
party shall be obligated to commence discussions relating to Phase Two and negotiation of the terms of any licenses to be granted to LabCorp until (a) such time as LipoScience has performed more than [***] Tests for LabCorp and its Affiliates
each calendar month for three (3) consecutive months, or (b) July 1, 2006, whichever is later. The actual transfer of the technology and/or effective date of the license agreement would not take place prior to such time as LipoScience
has performed more than [***] Tests for LabCorp and its Affiliates each calendar month for three (3) consecutive months. 

3.2 Regulatory Matters. LabCorp acknowledges and agrees that LipoScience has not applied for, made any submissions required for,
or obtained any approvals as of the date hereof which may be required from the United States Food and Drug Association or other regulatory authority, including any FDA 510(k) approvals, for the Test or the underlying intellectual property and
technology. In the event that LipoScience, or LabCorp, reasonably determines that any such approvals are necessary for performance of, or licensed under, Phase Two, the parties shall discuss in good faith the process and procedures required for such
approvals, which approvals, if any, shall be submitted and owned by LipoScience. 
 4. Payments to LipoScience. 

4.1 Service Fee. LabCorp will pay LipoScience a service fee equal to the Applicable Service Fee for each Test performed (except
Tests which must be repeated on the same sample at the customer’s request for quality assurance reasons or verification, and except Tests for which LabCorp does not invoice the appropriate payor and assume other billing activities as described

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

6 

 
in Section 2.2.b.) by LipoScience for LabCorp and its Affiliates, subject to the provisions of Sections 4.2, 4.3 and 4.6. 
 4.2 Best Faith Effort Factor Adjustment to the Applicable Service Fee.  

a. Promptly following the end of each month of the Term, LipoScience shall calculate the Best Faith Effort Factor and provide the BFE for
such month to LabCorp to the extent applicable. LabCorp will have twenty (20) days from receipt of the BFE to provide written notice to LipoScience if it reasonably disputes the calculation of the BFE If the BFE is less than [***], then the
Applicable Service Fee for that month will be increased by [***] per Test. If the BFE is [***] or more, but less than [***], then the Applicable Service Fee for the month shall be increased by [***] per Test. If the BFE is [***] or more, but less
than [***], then the Applicable Service Fee for the month will be increased by [***] per Test. If the BFE is [***] or greater, there will be no increase in the Applicable Service Fee for the month. 

b. At the first anniversary of the Effective Date, the parties agree to review the Best Faith Effort Factor adjustment and make such
revisions as may be agreed to by the parties. 
 c. Notwithstanding Section 4.2.a., if the number of Tests ordered by
LabCorp exceeds [***] in any calendar month and remains at or above [***] during each subsequent month of the Term, then this Section 4.2 and the Best Faith Effort Factor adjustment will no longer apply during the remainder of the Term. If the
number of Tests ordered by LabCorp decreases (or is) below [***] in any subsequent calendar month during the Term, then the Best Faith Effort Factor will apply for subsequent months until the criteria above for elimination of the Best Faith Effort
Factor is once again met. 
 d. If the Best Faith Effort Factor is less than or equal to [***] during any month during the Term,
then the parties shall promptly meet and review LabCorp’s business practices, and if (i) it is reasonably determined that the reason that the Best Faith Effort Factor is less than or equal to [***] is primarily due to LabCorp’s
business practices, and (ii) LabCorp does not modify such business practices to increase the Best Faith Effort Factor to more than [***] within 60 days following such month in which the Best Faith Effort Factor is less than or equal to [***],
then LipoScience shall have the right to terminate the Agreement in accordance with Section 6.2(d) hereof. 
 4.3
Applicable Service Fee Increased Based on Reimbursement Adjustment. Beginning on the later of January 1, 2006 or the date CMS establishes the New Rate, and continuing for the remainder of the Term, the Applicable Service Fees for each
month shall be increased by the RAF for that month, unless the NMR Average Reimbursement for the prior calendar quarter (as determined beginning at the end of the first calendar quarter of 2006 and continuing each quarter thereafter) was less
than an amount equal to the sum of the Current Average Reimbursement plus the RAF, in which case the Applicable Service Fees shall be increased by the Designated Amount for the subsequent calendar quarter. As used herein, the

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

7 

 
“Designated Amount” means an amount equal to the NMR Average Reimbursement for the prior calendar quarter minus the Current Average Reimbursement; provided,
however, that if the NMR Average Reimbursement for the prior calendar quarter was less than the Current Average Reimbursement, then the Designated Amount is zero (0). 
 4.4 Reporting and Payment of Applicable Service Fees. Within thirty (30) days following the end of each calendar month during Phase One (and thereafter if Services continue to be provided),
LipoScience will send LabCorp an itemized statement for the Applicable Service Fees payable for Services rendered to LabCorp and its Affiliates by LipoScience for the prior month. LabCorp agrees to remit payment to LipoScience for all undisputed
amounts within thirty (30) days after receipt of said statement and Test requisitions. In the event that LabCorp reasonably disputes an invoiced amount, to the extent commercially reasonable, LabCorp shall notify LipoScience within such
(30) day period after receipt of the statement. The parties agree to promptly negotiate in good faith to resolve any such disputes relating to invoiced amounts, including referring such matter to senior management if not resolved in a timely
manner. The statement must include the following information (to the extent available to LipoScience) in paper format: the total number of Tests performed during such month, and for each such Test the patient name, accession number, draw date, and
referring location. LipoScience will also respond to reasonable requests from LabCorp for additional information. Except as otherwise set forth in this Agreement, LipoScience shall look only to LabCorp for payment and shall not bill any patient or
third party for Services provided hereunder, except where LipoScience is required by law to bill such patients or third party directly or by LabCorp’s prior written consent. In such cases, LipoScience will notify LabCorp and the parties will
discuss the proper way to comply with applicable law. 
 4.5 Efforts. Except as set forth in Section 11
below, this Agreement shall not be construed to require (by implication or otherwise) any obligation on LabCorp and its Affiliates to request or perform any minimum number of Tests, or perform any minimum amount of effort in order to give rise to
payments to LipoScience. 
 4.6 Most Favored Terms. During any twelve (12) month period (measured annually
beginning on January 1, 2007) in which LabCorp and its Affiliates orders more Tests than any other Entity during the prior twelve (12) months, the prices payable by LabCorp and its Affiliates for the Test shall be no less favorable than
those provided by LipoScience to any other Entity. In the event LipoScience offers any such other Entity more favorable terms, LipoScience shall immediately notify LabCorp in writing and LabCorp may accept such terms by providing notice to
LipoScience. 
 4.7 No Other Payments. Except as specified in this Section 4, no other royalties, service
fees, or other payments shall be due from LabCorp or its Affiliates in exchange for the rights granted or obligations assumed by LipoScience under this Agreement. 
 5. Support. 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

8 

 5.1 Customer Service Telephone Support. LipoScience shall provide LabCorp and its
Affiliates with customer service telephone “hotline” support available 8:00 a.m. EST through 4:00 p.m. PST, Monday through Friday during Phase One. Such telephone support shall be toll-free and adequately staffed at all times in order to
ensure the prompt resolution of any and all customer service questions and issues of LabCorp. Such support shall be limited to technical questions on the format of the reports and compliance with Specimen Requirements. The hours of telephone support
may be extended or reduced by mutual written agreement of the parties, and LipoScience agrees to make commercially reasonable efforts to accommodate any request by LabCorp to extend such hours due to market demand. 

6. Term; Termination. 

6.1 Term. This Agreement shall become effective on the Effective Date. This Agreement shall continue in effect for a period
of three (3) years (unless sooner terminated as provided in this Agreement), whereupon it shall terminate. 
 6.2
Termination. In addition to the rights of termination provided elsewhere in this Agreement, and without limiting any other rights or remedies available to a party, the Term of this Agreement may be terminated: 

a. By either party because of any breach of the other party hereto in discharging or performing its duties and obligations under this
Agreement upon thirty (30) days prior written notice; provided, however, that if such defaulting party shall within the foregoing thirty (30) day period cure such default, then such notice of termination shall be of no
effect; 
 b. By LabCorp immediately upon written notice in the event that (i) all or substantially all of the assets of
LipoScience, or the Test, are sold to, acquired by or merged with a party that is a Competitor of LabCorp, or (ii) a Change of Control whereby a Competitor of LabCorp acquires control of LipoScience or the Test; 

c. By either party immediately upon written notice in the event that: the other party ceases to function as a going concern; a receiver
is appointed for the other party; a court orders the seizure or suspension of the other party’s rights or properties; or the other party otherwise takes advantage of any bankruptcy or insolvency law; 

d. By LipoScience upon thirty (30) days prior written notice in the event the criteria set forth in Section 4.2 d are met.

 6.3 Effect of Termination. The provisions of this Agreement which by their nature require performance following
termination of this Agreement, including without limitation Sections 2.10, 6.3, 7, 8, 9, 10 and 11.6, shall survive termination of this Agreement for any reason. Upon termination of this Agreement upon request each party shall return to the other
party such other party’s Confidential Information (including all copies, notes, summaries or other documentation incorporating Confidential Information), materials and property.  

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

9 

 7. Representations and Warranties. 

7.1 Representations of LipoScience. LipoScience hereby represents to LabCorp that: 

a. NEITHER LIPOSCIENCE NOR ANY OF ITS EMPLOYEES, AGENTS OR OWNERS HAVE BEEN DEBARRED, SUSPENDED, DECLARED INELIGIBLE, OR EXCLUDED FROM
MEDICARE/MEDICAID OR ANY OTHER FEDERAL OR STATE HEALTHCARE PROGRAM; 
 b. LipoScience is not a customer of LabCorp or its
Affiliates, and no physician or physician’s family member (i) shall receive or share directly or indirectly in the proceeds of this Agreement; or (ii) except as set forth on Exhibit G attached hereto, has an interest in
LipoScience’s business either directly or indirectly, through debt, equity, or otherwise. In such instances where a physician or physician’s family member has such an interest in LipoScience’s business, LabCorp and LipoScience shall
work together to assure that such interest is not a violation of 42 CFR Part 411 (the “Stark Regulations”) and any similar state or federal law or regulation; 
 c. LipoScience’s employees who will be performing the Services under this Agreement possess the necessary skill, education, and training; 

d. Where required by any applicable state laws or regulations, LipoScience and its employees have the necessary federal and state
licenses or certificates to perform the Services in a professional manner and are qualified to perform such Services, and LipoScience agrees to provide LabCorp with copies of such licenses or certificates upon written request; 

e. Prior to December 31, 2005, LipoScience shall complete and will thereafter maintain a commercially reasonable disaster recovery
plan for each assay it performs; 
 f. This Agreement does not contravene or constitute a default or violation of any provision
of applicable law or any agreement, commitment, or instrument to which LipoScience is bound; and 
 g. The Test protocol is
currently kept confidential by LipoScience, and to the best of LipoScience’s knowledge and belief, is unknown to and unavailable to any third parties, other than third parties to which LipoScience has disclosed the Test protocol under an
obligation of confidentiality. 
 7.2 Representations of LabCorp. LabCorp hereby represents to LipoScience that:

 a. NEITHER LABCORP NOR ANY OF ITS AFFILIATES, EMPLOYEES, AGENTS OR OWNERS HAVE BEEN DEBARRED, SUSPENDED, DECLARED INELIGIBLE,
OR EXCLUDED FROM MEDICARE/MEDICAID OR ANY OTHER FEDERAL OR STATE HEALTHCARE PROGRAM. 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

10 

 b. LabCorp’s employees who will be (i) obtaining, handling and shipping the
samples for Tests in accordance with Sample Requirements, and (ii) selling or billing for the Test under this Agreement possess the necessary skill, education, and training; 

c. Where required by any applicable state laws or regulations, LabCorp and its employees have the necessary federal and state licenses or
certificates to obtain, handle and ship samples in a professional manner and are qualified to obtain, handle and ship samples, and LabCorp agrees to provide LipoScience with copies of such licenses or certificates upon written request; and

 d. This Agreement does not contravene or constitute a default or violation of any provision of applicable law or any
agreement, commitment, or instrument to which LabCorp is bound. 
 7.3 Limitation of Liability. EXCEPT FOR
INDEMNIFICATION FOR THIRD PARTY CLAIMS OR BREACHES RELATING TO CONFIDENTIAL INFORMATION, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, OR INDIRECT DAMAGES OF ANY KIND WHATSOEVER IN CONNECTION WITH THIS AGREEMENT.

 8. Indemnification. 
 8.1 Indemnification of LabCorp. LipoScience agrees to indemnify and defend LabCorp and its Affiliates and its officers, employees, and their respective successors, heirs and assigns (the
“Indemnitees”), against any claim of liability, damage, loss or expenses (including reasonable attorney’s fees and expense of litigation) incurred by or imposed upon the Indemnitees or any one of them in connection with any third
party claims, suits, actions, demands or judgments to the extent arising out of (i) the negligent or intentional acts of LipoScience, or (ii) any breach of any provision of this Agreement by LipoScience; provided that:
(a) LabCorp promptly notifies LipoScience of the claim in writing; (b) LipoScience has sole control of the defense and all related settlement negotiations; and (c) LabCorp provides LipoScience with the assistance, information and
authority necessary to perform LipoScience’s obligations under this Section. 
 8.2 Indemnification of LipoScience.
LabCorp agrees to indemnify and defend LipoScience and its officers, employees, and their respective successors, heirs and assigns (the “Indemnitees”), against any claim of liability, damage, loss or expenses (including reasonable
attorney’s fees and expense of litigation) incurred by or imposed upon the Indemnitees or any one of them in connection with any third party claims, suits, actions, demands or judgments to the extent arising out of (i) the negligent or
intentional acts of LabCorp, or (ii) any breach of any provision of this Agreement by LabCorp; provided that: (a) LipoScience promptly notifies LabCorp of the claim in writing; (b) LabCorp has sole control of the defense and
all related settlement negotiations; and (c) LipoScience provides LabCorp with the assistance, information and authority necessary to perform LabCorp’s obligations under this Section. 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

11 

 9. Insurance. LipoScience hereby represents that is currently maintaining, and LipoScience agrees to
continue to maintain, at its sole expense, during the Term, insurance as specified on Exhibit E attached hereto. Each such insurance policy shall include a provision naming LabCorp as an additional insured and a provision providing that
thirty (30) days’ written notice shall be given to LabCorp before cancellation, cessation or material modification of coverage. LipoScience agrees that it shall either maintain continuous “claims made” coverage thereafter for a
period of five (5) years or secure a five (5) year “tail” policy. 
 10. Confidentiality. 

10.1 Confidential Information. Each party acknowledges that from time to time during the Term of this Agreement it may come into
possession of certain Confidential Information of or concerning the other party. Each party agrees that, during the Term and for a period of Ten (10) years thereafter, it shall not, directly or indirectly, (i) use the other party’s
Confidential Information, or (ii) disclose or otherwise make available to any third party any Confidential Information of the party; except in each case as authorized by the other party under this Agreement or otherwise in writing. The
obligations of this Section shall not apply to (a) information which is or becomes available to the general public through no fault of the receiving party; (b) information which has been disclosed to the receiving party by a third party
not subject to an obligation of confidentiality to the disclosing party; (c) information which was rightfully in the possession of the receiving party prior to disclosure by the disclosing party; or (d) information which was independently
developed by the receiving party without the benefit of information received from the disclosing party. 
 10.2 Press
Releases; Publicity. Each party acknowledges that the other party has a proprietary interest in its legal and business brands, name and reputation. The parties agree to mutually prepare and agree upon a press release within five (5) days of
the Effective Date, and from and after the publication of such press release, each party shall be entitled to make or publish any statement limited to the contents of such press release. Other than such statements, each party agrees it will not make
reference to or use the other party’s name nor shall it mention or describe this Agreement in its advertising, marketing or promotional materials or other publications or materials without obtaining the prior written approval of the other
party, which shall not be unreasonably withheld or delayed; provided, however, that LipoScience shall have the right to list LabCorp in any general listing of its customers, provided that the reference to LabCorp is in the same format and size as
references to other customers and clients and does not give greater weight to LabCorp’s name than any other customer or client. 
 11.
Marketing. 
 11.1 Availability. LabCorp shall make commercially reasonable efforts to make the Test available to
its clients no later than July 1, 2005. 
 11.2 Promotion. For the twelve month period, to the extent consistent
with applicable laws and regulations, beginning January 1, 2006, LabCorp agrees that: 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

12 

 a. The Test will be promoted to no lesser degree than other advanced lipid tests offered by
LabCorp, including without limitation, [***], any lipoprotein phenotyping tests, lipoprotein subfractionation profile tests, cholesterol electrophoresis tests and expanded lipoprotein analysis test (“Advanced Lipid Tests”); and 

b. The LabCorp marketing and sales personnel shall receive no lesser incentive(s) for selling and promoting the Test than for selling and
promoting other Advanced Lipid Tests offered by LabCorp. 
 c. To the extent consistent with peer-reviewed scientific, medical
or laboratory publications, LabCorp shall use commercially reasonable efforts to help ensure that LabCorp’s technical publications concerning, and clinical positioning of, the Test by LabCorp are consistent with LipoScience’s clinical
positioning of the Test. 
 11.3 Review. After January 1, 2007, the parties shall review and consult annually
regarding LabCorp’s marketing efforts with regard to the Test. 
 11.4 Positioning. To the extent consistent
with peer-reviewed scientific, medical or laboratory publications, during the Term, LabCorp shall position the Test in that it will make the Test available through its network broadly on a national basis and at least as broadly and on a commensurate
basis as it offers other Advanced Lipid Tests.  
 11.5 Sole Remedy. LipoScience’s sole and exclusive remedy
for LabCorp’s breach of Section 11.2 and/or Section 11.4 shall be termination of this Agreement pursuant to Section 6.2.a; provided however, in the event of LabCorp’s breach of Section 11.2 and/or Section 11.4,
LabCorp shall pay LipoScience an additional amount of [***] for each Test performed for LabCorp by LipoScience from the effective date of this Agreement. 
 11.6 Marketing Warranties. The parties and their respective Affiliates, employees, agents and representatives shall conduct all promotion, marketing and sales activities in connection with
the Test in compliance with all applicable laws and regulations. 
 11.7 Trademarks. Consistent with LipoScience’s
positioning of the Test, LabCorp shall use the LipoScience Trademarks to identify the Tests in its marketing, sales and promotion of the Tests. All such uses of the LipoScience Trademarks and the good will developed therein shall inure to the
benefit of LipoScience. LabCorp will conduct its business and promote the Tests in conformity with good business practices and in a manner that reflects favorable on the good will and reputation of LipoScience. LabCorp will not engage in any
deceptive, misleading, or unethical practices relating to its promotion, marketing, sale, performance or billing practices for the Tests. LabCorp will not modify, delete, obliterate or otherwise obscure any trademark or patent markings on the Test
results reported to LabCorp or its clients. 
 12. Collaborative Assistance. To the extent commercially reasonable, LabCorp will provide
assistance to LipoScience with respect to initiatives related to obtaining appropriate reimbursement for the Test and appropriate Medicare coverage for relevant CPT Codes. In 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

13 

 
addition, to the extent consistent with applicable law and regulation, LabCorp will provide LipoScience physician ordering data by “zip 3” code on a monthly basis and “full
zip” code data on a quarterly basis. In no event shall LabCorp offer LipoScience less information regarding physician ordering data than that which is provided to manufacturers of other lipid tests offered by LabCorp. LipoScience’s sole
and exclusive remedy for breach of this Section 12 shall be termination of this Agreement pursuant to Section 6.2.a. 
 13.
Effective Time of Performance. The parties agree that (i) the date on which the Entity performing the Test sends the Test result to the recipient shall be the applicable date upon which a Test shall be deemed to have been performed; and
(ii) the date on which LipoScience receives a Test request and the appropriate sample in accordance with the Sample Requirements shall be the applicable date upon which a Test shall be deemed to have been ordered from LipoScience. 

14. Compliance with Laws. The terms of this Agreement are intended to be in compliance with federal, state and local statutes, regulations and
ordinances applicable on the date this Agreement is signed, including, but not limited to, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). The parties agree to execute such amendments as may be necessary
for HIPAA compliance as additional regulations are promulgated or become final and effective. 
 15. Further Assurances. LipoScience
agrees that it will perform all other acts and execute and deliver all other documents as may be necessary or appropriate to carry out the intent and purposes of this Agreement. 
 16. Assignment and Benefit. Except as expressly set forth in this Agreement, neither this Agreement nor the respective rights and obligations of the parties under this Agreement may be assigned,
transferred, delegated or subcontracted in whole or in part, by either party to any other Entity without the prior written consent of the other party. Subject to the prior sentence, the rights, duties, and obligations of the parties under this
Agreement shall inure to the benefit and shall be binding upon their respective successors and permitted assigns. Notwithstanding the foregoing, either party may assign this Agreement without the consent of the other party in connection with any
sale or merger which involves substantially all of the assets of such party of the business to which this Agreement relates. 
 17.
Status of Parties. The Services will be rendered by LipoScience under this Agreement as an independent contractor. This Agreement creates no relationship of joint venturers, partners, or principal and agent between the parties. Neither
LipoScience nor its employees or agents will be deemed to be employees or agents of LabCorp or any of its Affiliates and as such, LipoScience’s employees will not be covered under any of the benefit programs of LabCorp or its Affiliates,
including, but not limited to worker’s compensation. Further, neither party shall be authorized to act on behalf of, or otherwise bind the other party. 
 18. Notices. Any notice contemplated or required or permitted to be given under this Agreement shall be sufficient if in writing and prepaid and if (i) delivered personally, (ii) sent
registered or certified mail, return receipt requested, (iii) by express delivery service (such as 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

14 

 
Federal Express) where the recipient must execute its receipt, or (iv) sent by facsimile and immediately confirmed by registered or certified mail or express delivery, to the parties’
respective addresses below, or to such other addresses as either party hereto may hereafter designate in writing. 
  

			
	LipoScience:	  	LabCorp:
	LipoScience, Inc.	  	Laboratory Corporation of America Holdings
	2500 Sumner Blvd.	  	430 South Spring St.
	Raleigh, NC 27616	  	Burlington, NC 27215
	Attn: Chief Operating Officer	  	Attn: General Counsel
		
	with a copy also sent to:	  	with a copy also sent to:
		
	General Counsel	  	Parker Poe Adams & Bernstein, LLP
		  	P.O. Box 389
		  	150 Fayetteville Street Mall, Suite 1400
		  	Raleigh, North Carolina, 27602-0389
		  	Attn: John R. Erwin, Esq.
		  	Fax: 919-834-4564

 19. Governing Law. This Agreement, and any dispute or controversy arising out of or relating thereto, shall
in all respects be governed by and construed according to the laws of the State of North Carolina (excluding its conflicts of law provisions). 
 20. Miscellaneous. This Agreement may be executed in counterparts in order to provide each party with a fully-executed original hereof. Except as otherwise provided herein, this Agreement may not
be changed, modified or amended except by an agreement in writing signed by both parties. The provisions of this Agreement are hereby deemed by the parties to be severable, and the invalidity or unenforceability of any one or more of the provisions
of this Agreement shall not affect the validity an enforceability of the remaining provisions thereof. The waiver by any party to this Agreement of any breach or violation of any provisions of this Agreement by any other party hereto shall not
operate as a waiver of any other breach. Titles and headings of sections of this Agreement are for convenience and reference only and shall not affect the construction of any provisions of this Agreement. All exhibits attached hereto are hereby
incorporated herein by reference. This Agreement reflects the complete understanding of the parties and constitutes their entire agreement regarding its subject matter, superseding all prior verbal or written negotiations, representations,
agreements, understandings, and statements regarding the subject matter herein. 
 [SIGNATURES ON FOLLOWING PAGE]

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

15 

 IN WITNESS WHEREOF, the parties have executed this Agreement by signature of their
respective duly authorized representatives as of the Effective Date. 
  

									
	LipoScience, Inc.	 		 	Laboratory Corporation of America Holdings
					
	By:	 	 /s/ Richard Pinnola
	 		 	By:	 	 /s/ Pamela J. Sherry

									
					
	Printed Name:	 	 Richard Pinnola
	 		 	Printed Name:	 	 Pamela J. Sherry

									
					
	Title:	 	 Chief Operating Officer
	 		 	Title:	 	 Senior Vice President

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

16 

 *** Text Omitted and Filed Separately 

Confidential Treatment Requested 
 Under 17 CFR §§ 200.80(b)(4) and 230.406 
 Exhibit A

 Trademarks, Service Marks and Applications 
 LIPOSCIENCE 
 LIPOPROFILE 
 

 
 NMR LIPOPROFILE 
 

 
 UNCOVER THE UNSEEN RISK OF DISEASE 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 *** Text Omitted and Filed Separately 

Confidential Treatment Requested 
 Under 17 CFR §§ 200.80(b)(4) and 230.406 
 

 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 

 *** Text Omitted and Filed Separately 

Confidential Treatment Requested 
 Under 17 CFR §§ 200.80(b)(4) and 230.406 
 Exhibit C 

Sample Requirements 
 

 
 Specimen Collection and Transport Instructions 

Patient Preparation 

Blood collection should be standardized to minimize preanalytic variation. The patient should sit quietly for five minutes before blood
collection and tourniquet use should be minimized. 
 Fasting is required for an accurate triglyceride result; fasting status
does not substantially affect other components of the NMR Lipoprofile®. 
 Acceptable Specimens 

EDTA plasma (lavender-top) is the preferred specimen for the NMR Lipoprofile; Serum (red-top) is also acceptable. EDTA plasma should be
centrifuged immediately; serum specimens should be allowed to clot for ~30 minutes before centrifugation. Serum or plasma should be transferred to a separate, tightly capped vial for transport. Place barcode label vertically on specimen transfer
vial. 
 Gel barrier tubes are NOT acceptable. Other additives are not acceptable. 

A minimum of 1 mL serum or plasma is required for the NMR Lipoprofile®, 2 mL is preferred. 

Refrigerate specimens until shipped. 
 Shipping Instructions 
 Lay specimens in Styrofoam box and cover with an
adequate number of frozen ice brick(s). Make sure that specimens are properly labeled and requisitions or manifests are complete and accurate. Include requisitions or manifests in same shipping container as specimens. 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 *** Text Omitted and Filed Separately 

Confidential Treatment Requested 
 Under 17 CFR §§ 200.80(b)(4) and 230.406 
 Exhibit D

 Medicare + Choice Provisions 

 

	a)	LipoScience agrees to give LabCorp, HHS, the Comptroller General or their designees the right to audit, evaluate, and inspect books, contracts, records and other
patient documentation for the period of four (4) years from termination of the Agreement or from the date of completion of any audit, whichever is later. 

 

	b)	LipoScience will safeguard the privacy of any information that identifies a particular Member. To this end, LipoScience will (i) release information from, or
copies of, records only to authorized individuals; (ii) ensure that unauthorized individuals cannot gain access to or alter patient records; (iii) maintain Member records and information in an accurate and timely manner; (iv) ensure
timely access by Members to the records and information that pertain to them; (v) ensure that original records are released only in accordance with Federal or State laws, court orders, or subpoenas; and (vi) abide by all Federal and State
laws regarding confidentiality and disclosure for medical records, other health information, and member information. 

  

	c)	LipoScience agrees to provide services and access services under this Agreement in a manner consistent with professionally recognized standards of health care.

  

	d)	LipoScience agrees that in no event, including, but not limited to nonpayment by LabCorp, LabCorp’s insolvency or breach of this Agreement, shall LipoScience bill,
charge, collect a deposit from, seek compensation, remuneration or reimbursement from, or have any recourse against Members of health plans or persons acting on their behalf for services provided pursuant to this Agreement. LipoScience agrees that
this provision shall survive the termination of this Agreement regardless of the cause giving rise to termination and shall be construed to be for the benefit of the Member. This provision supersedes any oral or written agreement to the contrary now
existing or hereafter entered into between the LipoScience and the Member or persons acting on Member’s behalf. 

  

	e)	Any services or other activity performed by LipoScience under the Agreement will be consistent and comply with all applicable Medicare laws, regulations, and CMS
instructions, including all applicable requirements of the Medicare + Choice program. LipoScience shall comply with the Medicare + Choice appeals procedures, including the gathering and forwarding of information on appeals to the Medicare + Choice
organizations for which LabCorp is a participating provider, as necessary. 

  

	f)	LipoScience acknowledges and agrees that the Medicare + Choice organizations for which LabCorp is a participating provider are obligated to oversee and be accountable
to CMS for the services provided hereunder. To this end, performance of activities under the Agreement will be monitored on an ongoing basis by Medicare + Choice organizations for which LabCorp is a participating provider. 

 

	g)	 LipoScience understands that Medicare + Choice organizations may only delegate activities or functions in a manner consistent with the requirements set
forth at 42 C.F.R. 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	
§ 422.502(i)(4). To the extent that LipoScience further delegates services to be performed under the Agreement, such arrangements shall comply with all applicable Medicare + Choice program
requirements. 

  

	h)	LabCorp agrees to render payment to LipoScience within 45 days of the receipt of invoice, provided that the invoice is accompanied by all information requested by
LabCorp to invoice the responsible party and to report encounter data to the appropriate party. 

  

	i)	To the extent required by CMS, LipoScience agrees to submit to LabCorp encounter data for services rendered to Members, at least to the extent necessary to characterize
the context and purposes of each encounter with a Member. Said encounter data shall be submitted by LipoScience in compliance with CMS requirements concerning timeliness and accuracy, including an attestation as to the accuracy, completeness and
truthfulness of the encounter data. Medicare + Choice organizations for which LabCorp is a participating provider must certify to CMS that they are submitting accurate, complete and truthful encounter data to the best of their knowledge, information
and belief. 

  

	j)	LipoScience acknowledges and agrees that payments that it receives from LabCorp for services rendered to Medicare + Choice Members are, in whole or in part, from
Federal funds, and LipoScience is therefore subject to laws applicable to entities receiving federal funds, including but not limited to Title VI of the Civil Rights Act of 1964 as implemented by regulations at 45 CFR part 84; The Age Discrimination
Act of 1975 as implemented by regulations at 45 CFR part 91; The Rehabilitation Act of 1973; The Americans With Disabilities Act; and all other laws applicable to recipients of Federal funds. 

 

	k)	LipoScience hereby represents and warrants that LipoScience and its employees providing services hereunder maintain full participation status with the Medicare program
and are not excluded from participation in Medicare or any other governmental program. LipoScience represents and warrants that it shall not employ or contract with any individual or entity who is excluded from participation in Medicare under
Section 1128 or 1128A of the Social Security Act. LipoScience shall notify LabCorp immediately in the event that LipoScience is excluded from participating under Medicare or any other governmental program. 

 

	1)	LipoScience shall cooperate with applicable activities of independent quality review and improvement organizations pertaining to services provided by LipoScience.
LipoScience also agrees to comply with all applicable policies and procedures of the Medicare + Choice organization for which LabCorp is a participating provider, including medical policies, quality assurance programs and medical management
programs. 

  

	m)	If LipoScience is a physician and LabCorp suspends or terminates the Agreement, LabCorp agrees to provide written notice to LipoScience of the reasons for the action
and of LipoScience’s right to appeal the action and the process and timing for requesting a hearing. 

  

	n)	This Agreement (to the extent it relates to Medicare + Choice Members during Phase One) may be terminated by either party without cause upon a sixty (60) day prior
written notice to the other party. 

 LipoScience and LabCorp agree that in the event of a conflict between the terms of the Agreement and the
terms of this Exhibit D, the terms of this Exhibit D will apply with respect to the services provided to the Medicare + Choice Members. The terms of the Agreement shall control in all other respects. 

 *** Text Omitted and Filed Separately 

Confidential Treatment Requested 
 Under 17 CFR §§ 200.80(b)(4) and 230.406 
 Exhibit E

 Insurance 
 [***] 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 *** Text Omitted and Filed Separately 

Confidential Treatment Requested 
 Under 17 CFR §§ 200.80(b)(4) and 230.406 
 Exhibit F

 LABORATORY CORPORATION OF AMERICA HOLDINGS 

SCHEDULE OF AFFILIATES AND TRADE NAMES ASSOCIATED WITH THE 
 ORDERING OF LABORATORY TESTS 
 As of June 7, 2005 

Laboratory Corporation of America Holdings (LCAH) (Parent) 
 Subsidiaries: 
 Laboratory Corporation of America (LCA) 

DIANON Systems, Inc. 
 Dynacare Laboratories,
Inc. 
  

	 	•	 	 U.S. Joint Ventures 

  

	 	•	 	 UHS/DL, LP (Tennessee) 

  

	 	•	 	 DL/UHS, Inc. (Tennessee) 

  

	 	•	 	 United Dynacare LLC (Milwaukee) 

  

	 	•	 	 U. S. Subsidiaries 

  

	 	•	 	 Dynacare Holdco LLC 

  

	 	•	 	 Dynacare Northwest Inc. 

  

	 	•	 	 Clinical Laboratories Cheyenne 

  

	 	•	 	 Dynacare Southwest Laboratories, Inc. 

  

	 	•	 	 HHD Gen Par Inc. 

  

	 	•	 	 HH/DL LP 

  

	 	•	 	 SW/DL LP 

  

	 	•	 	 Dynacare Louisiana, L.L.C. 

Clinical Laboratories, Inc. 
 Viro-Med
Laboratories, Inc. 
 National Genetics Institute 
 Path Lab Holdings, Inc. 
 Path Lab, Inc. d/b/a LabCorp 

Center for Genetic Services, Inc. 
 US Pathology
Labs, Inc. 
  

	 	•	 	 Accupath Diagnostics Laboratories, Inc. 

  

	 	•	 	 US Labs Fountain Valley, Inc. 

  

	 	•	 	 US Labs, Inc. 

 Esoterix,
Inc. 
  

	 	•	 	 Allergy Testing Laboratories, Inc. 

  

	 	•	 	 Applied Genetics, Inc. 

  

	 	•	 	 Colorado Coagulation Consultants, Inc. 

  

	 	•	 	 Cytometry Associates, Inc. 

  

	 	•	 	 Endocrine Sciences, Inc. 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	•	 	 The Esoterix Center for Infectious Diseases, Inc. 

  

	 	•	 	 Long Beach Genetics, Inc. 

  

	 	•	 	 Molecular Genetics, Inc. 

  

	 	•	 	 Esoterix Pathology Practice Group, P.C. 

  

	 	•	 	 Esoterix Colorado Pathology Practice Group, P.C. 

  

	 	•	 	 Center for Clinical Trials 

Trade names: 
 Dynagene 

ARL (Alabama Reference Lab) 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 *** Text Omitted and Filed Separately 

Confidential Treatment Requested 
 Under 17 CFR §§ 200.80(b)(4) and 230.406 
 Exhibit G

 Physicians or Physician’s Family Members who are stockholders of LipoScience 

[***] 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 *** Text Omitted and Filed Separately 

Confidential Treatment Requested 
 Under 17 CFR §§ 200.80(b)(4) and 230.406 
 AMENDMENT TO AGREEMENT

 This Amendment to Agreement (“Amendment”) is made as of this 1st day of July, 2006 (the “Amendment Date”), by and
between Laboratory Corporation of America Holdings, a Delaware corporation having a place of business at 430 South Spring Street, Burlington, North Carolina 27215 (“LabCorp”), and LipoScience, Inc., a Delaware corporation having a place of
business at 2500 Sumner Blvd., Raleigh, NC 27616 (“LipoScience”). 
 Recitals 

WHEREAS, LabCorp and LipoScience have previously entered into an Agreement, effective June 8th, 2005, regarding the NMR LipoProfile® test (the
“Agreement”); and 
 WHEREAS, both parties desire to modify and amend the Agreement to facilitate commercialization of products
thereunder. 
 NOW, THEREFORE, in consideration of the promises and mutual covenants herein contained, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 
  

	1.	Section 1. Definitions. 

 Part “b.” of the definition of “Applicable Service Fee” in Section 1 of the Agreement is hereby amended in its entirety and replaced with the following: 

“b. For Tests performed between July 1, 2006 and December 31, 2006, and provided that Tier 1 Promotion is continuously
provided by LabCorp during such six-month period: 
 (i) [***] per Test received from LabCorp and its Affiliates, provided that
if the number of Tests received from LabCorp and its Affiliates is less than [***] during such six month period, then LabCorp shall additionally pay to LipoScience: 
 1. [***] for each unperformed Test between [***] and [***], and 
 2. [***] for
each unperformed Test less than [***]. 
 (ii) In no event will the amounts payable under Sections b(i)1 and b(i)2 above,
exceed [***]. 
 c. For Tests performed after December 31, 2006 until the end of the Term, and provided that Tier 1
Promotion is continuously provided by LabCorp: 
 (i) If greater than [***] Tests were received by LipoScience from LabCorp and
its Affiliates during the six month period from July 1, 2006 through December 31, 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

1 

 
2006 under Section b. above, then [***] per Test received from LabCorp and its Affiliates without regard to the number of tests received by LipoScience from LabCorp and its Affiliates during any
period after December 31, 2006, 
 (ii) If less than [***] Tests were received from LabCorp and its Affiliates during the
six month period from July 1, 2006 through December 31, 2006 under Section b. above, then for each calendar half-year period of 2007 and 2008 (which period in 2008 being less than a calendar half-year shall be prorated with respect to the
number of Tests), the Applicable Service Fee shall be [***] per Test received from LabCorp and its Affiliates; provided, however that LabCorp shall additionally pay to LipoScience: 

1. [***] for each unperformed Test between [***] and [***], and 

2. [***] for each unperformed Test less than [***]. 
 (iii) In no event will the amounts payable under Sections c(ii)1 and (ii)2 above, exceed [***] for each such calendar half-year period.” 

 

	2.	Section 4.1 Service Fee is amended to remove the reference to Section 4.3. 

 

	3.	Section 4.3 Applicable Service Fee Increased Based on Reimbursement Adjustment is deleted in its entirety. 

 

	4.	Section 4.4 Reporting and Payment of Applicable Service Fees. 

 The first sentence of Section 4.4 of the Agreement is hereby amended and replaced with the following: 
 “Within thirty (30) days following the end of each calendar month during Phase One (and thereafter if Services continue to be provided) in which LabCorp does not provide Tier 1 Promotion,
LipoScience will send LabCorp an itemized statement for the Applicable Service Fees payable for Services rendered to LabCorp and its Affiliates by LipoScience for the prior month. If LabCorp continues to provide Tier 1 Promotion during Phase One
(and thereafter if Services continue to be provided), then in addition to sending the monthly itemized statements as described in the prior sentence, within thirty (30) days following the end of each of December 31,
2006, June 30, 2007, December 31, 2007 and June 8, 2008, LipoScience will send LabCorp an itemized statement for the Applicable Service Fees payable pursuant to subsections b(i)1., b(i)2., or c(ii), as applicable, of the
definition of “Applicable Service Fee” in Section 1.” 
  

	4.	No other Amendments 

 Except as
specifically modified herein, the Agreement shall remain in full force and effect as originally executed. 
  

	5.	Entire Agreement; Governing Law 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

2 

 The Agreement, as amended by this Amendment, constitutes and contains the entire
understanding and agreement of the parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, understandings and agreements between the parties. This Amendment, and any dispute or controversy arising out of
or relating thereto, shall in all respects be governed by and construed according to the laws of the State of North Carolina (excluding its conflicts of law provisions). 

 

	6.	Capitalized Terms 

 Capitalized
terms used but not defined herein shall have the meaning ascribed to them in the Agreement. 
 IN WITNESS WHEREOF, the parties
hereto have caused this Amendment to be executed by their duly authorized representatives, effective as of the Amendment Date first written above. 
  

									
	LipoScience, Inc.	 	Laboratory Corporation of America Holdings
					
	By:	 	 /s/ Richard Pinnola
	 		 	By:	 	 /s/ Andrew R. Ginsberg

					
	Name:	 	 Richard Pinnola
	 		 	Name:	 	 Andrew R. Ginsburg

					
	Title:	 	 COO
	 		 	Title:	 	 VP, Marketing

					
	Date:	 	 8/17/06
	 		 	Date:	 	 8/31/06

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

3 

 *** Text Omitted and Filed Separately 

Confidential Treatment Requested 
 Under 17 CFR §§ 200.80(b)(4) and 230.406 
 AMENDMENT NO. 2 TO
AGREEMENT 
 This Amendment No. 2 to Agreement (“Amendment”) is made as of this 27th day of September, 2007 (the
“Amendment Date”), by and between Laboratory Corporation of America Holdings, a Delaware corporation having a place of business at 430 South Spring Street, Burlington, North Carolina 27215 (“LabCorp”), and LipoScience, Inc., a
Delaware corporation having a place of business at 2500 Sumner Blvd., Raleigh, NC 27616 (“LipoScience”). 
 Recitals

 WHEREAS, LabCorp and LipoScience have previously entered into an Agreement, effective June 8, 2005, regarding the NMR
LipoProfile® test (the “Agreement”); and 
 WHEREAS, LabCorp and LipoScience have previously entered into an Amendment to
Agreement, effective July 1, 2006 (the “Amended Agreement”); and 
 WHEREAS, LabCorp and LipoScience desire to further modify and
amend the Amended Agreement to facilitate commercialization of products thereunder. 
 NOW, THEREFORE, in consideration of the promises and
mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 

 

	1.	Section 1. Definitions. 

 A. Parts “a.” and “b” of the definition of “Applicable Service Fee” in Section 1 of the Amended Agreement are hereby amended in their entirety and replaced with the
following, and part “c” of the definition of “Applicable Service Fee” in Section 1 of the Amended Agreement is hereby deleted in its entirety: 
 “a. For Tests performed between July 1, 2007 and December 31, 2007 (and during which time LabCorp warrants that it will continue to provide Tier 1 Promotion for the Test): 

 

	 	(i)	[***] per Test received from LabCorp and its Affiliates 

 b. For Tests performed from January 1, 2008 until the end of the Term: 
  

	 	(i)	Provided that Tier 1 Promotion is continuously provided by LabCorp for the Test in each scenario set forth in this Section b(i) below, [***] per Test received from
LabCorp and its Affiliates; provided however, once LipoScience has performed at least [***] Tests for LabCorp and its Affiliates per calendar month for each of three consecutive calendar months at any time after January 1, 2008, then the price
per Test shall be [***], which price change 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

1 

	 	
shall be effective as of the beginning of the calendar month following such three consecutive calendar month period; and 

 

	 	(ii)	If Tier 1 Promotion is not continuously provided by LabCorp for the Test from the period of January 1, 2008 until the end of the Term, then the price per Test
shall revert to [***] per Test received from LabCorp and its Affiliates, which price change shall be effective as of the date that the Test loses its Tier 1 Promotion status.” 

B. The terms “Baseline LipoScience Tests”, “Best Faith Effort Factor (or ‘BFE’)”, “Current Average
Reimbursement”, “Current Rate”, “New Rate”, “NMR Average Reimbursement”, “Reimbursement Adjustment Factor (or “RAF’)” set forth in Section 1 of the Amended Agreement are each deleted in
their entirety. 
 C. The following shall be added as a defined term under Section 1: 

 

	 	(i)	“Lipid Panel Add-On” means a standard lipid panel assay which may be added to the Test at the request of the customer at no additional cost. The addition of
the Lipid Panel Add-On to the Test is subject to scientific and compliance approval and acceptance by LabCorp. 

  

	2.	Section 4.1 Service Fee is amended to remove the reference to Section 4.2. 

 

	3.	Section 4.2 Best Faith Effort Factor Adjustment to the Applicable Service Fee is deleted in its entirety. 

 

	4.	Reporting and Payment of Applicable Service Fees. 

 The first sentence of Section 4.4 of the Amended Agreement is hereby amended and replaced with the following: 
 “Within thirty (30) days following the end of each calendar month during Phase One (and thereafter if Services continue to be provided), LipoScience will send LabCorp an itemized statement for
the Applicable Service Fees payable for Services rendered to LabCorp and its Affiliates by LipoScience for the prior month.” 
  

	5.	Section 6.1 Term, is amended in its entirety as follows: 

 This Agreement shall become effective on the Effective Date. This Agreement shall continue in effect for a period of three (3) years and will be automatically renewed on a year to year basis
thereafter until one party provides the other party with ninety (90) days’ written notice of termination prior to any yearly anniversary renewal date, or unless sooner terminated as provided in this Agreement. 

 

	6.	No other Amendments 

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

2 

 Except as specifically modified herein, the Amended Agreement shall remain in full force and
effect as originally executed. 
  

	7.	Entire Agreement; Governing Law 

The Amended Agreement, as further amended by this Amendment, constitutes and contains the entire understanding and agreement of the
parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, understandings and agreements between the parties. This Amendment, and any dispute or controversy arising out of or relating thereto, shall in all
respects be governed by and construed according to the laws of the State of North Carolina (excluding its conflicts of law provisions). 
  

	8.	Capitalized Terms 

 Capitalized
terms used but not defined herein shall have the meaning ascribed to them in the Amended Agreement. 
 IN WITNESS WHEREOF, the
parties hereto have caused this Amendment to be executed by their duly authorized representatives, effective as of the Amendment Date first written above. 
  

									
	LipoScience, Inc.	 		 	Laboratory Corporation of America Holdings
					
	By:	 	 /s/ Richard Pinnola
	 		 	By:	 	 /s/ Ben R. Miller

					
	Name:	 	 Richard Pinnola
	 		 	Name:	 	 Ben R. Miller

					
	Title:	 	 COO
	 		 	Title:	 	 Executive VP

					
	Date:	 	 9/18/07
	 		 	Date:	 	 9/27/07

  
 [***] = Certain information
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]